US20160045504A1 - Compositions and methods for treatment of leukemia - Google Patents
Compositions and methods for treatment of leukemia Download PDFInfo
- Publication number
- US20160045504A1 US20160045504A1 US14/665,600 US201514665600A US2016045504A1 US 20160045504 A1 US20160045504 A1 US 20160045504A1 US 201514665600 A US201514665600 A US 201514665600A US 2016045504 A1 US2016045504 A1 US 2016045504A1
- Authority
- US
- United States
- Prior art keywords
- compound
- mll
- substituted
- compounds
- menin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C1=C([2*])C2=C([W]C3C([5*])C([6*])[Y]([3*])C([8*])C3[7*])N=C([4*])N=C2C1 Chemical compound [1*]C1=C([2*])C2=C([W]C3C([5*])C([6*])[Y]([3*])C([8*])C3[7*])N=C([4*])N=C2C1 0.000 description 10
- OJAKSSMAOUQJNL-UHFFFAOYSA-N CC1(C)CN=C(N2CCN(C3=C4C=C(CC5=CC=CC=C5)SC4=NC=N3)CC2)S1 Chemical compound CC1(C)CN=C(N2CCN(C3=C4C=C(CC5=CC=CC=C5)SC4=NC=N3)CC2)S1 OJAKSSMAOUQJNL-UHFFFAOYSA-N 0.000 description 2
- GEMHNBVSXWLMQX-UHFFFAOYSA-N CC1=CC2=C(N3CCN(C4=CC=CC=C4)CC3)N=CN=C2S1.Cl Chemical compound CC1=CC2=C(N3CCN(C4=CC=CC=C4)CC3)N=CN=C2S1.Cl GEMHNBVSXWLMQX-UHFFFAOYSA-N 0.000 description 2
- DXGOGPHKPIGZBO-UHFFFAOYSA-N CCC1=CC2=C(NCC3CCN(CC4=CC=CC(C)=C4)CC3)N=CN=C2S1 Chemical compound CCC1=CC2=C(NCC3CCN(CC4=CC=CC(C)=C4)CC3)N=CN=C2S1 DXGOGPHKPIGZBO-UHFFFAOYSA-N 0.000 description 2
- SRQYLNYQAPCPIR-UHFFFAOYSA-N CCCC1=CC2=C(N3CCN(C4=NCC(C)(C)S4)CC3)N=CN=C2S1 Chemical compound CCCC1=CC2=C(N3CCN(C4=NCC(C)(C)S4)CC3)N=CN=C2S1 SRQYLNYQAPCPIR-UHFFFAOYSA-N 0.000 description 2
- NECZWBPRZWSOSU-UHFFFAOYSA-N O=C(CC1=NC(C2=CC=C(F)C=C2)=CF1)N1CCOCC1 Chemical compound O=C(CC1=NC(C2=CC=C(F)C=C2)=CF1)N1CCOCC1 NECZWBPRZWSOSU-UHFFFAOYSA-N 0.000 description 2
- WZPNVYWWPILWJK-UHFFFAOYSA-N C1=CC=C(C2=CC3=C(N4CCN(C5=NC=CS5)CC4)N=CN=C3S2)C=C1 Chemical compound C1=CC=C(C2=CC3=C(N4CCN(C5=NC=CS5)CC4)N=CN=C3S2)C=C1 WZPNVYWWPILWJK-UHFFFAOYSA-N 0.000 description 1
- DJBOBXSNRUYPEJ-UHFFFAOYSA-N C1=CC=C(N2CCN(C3=NC=NC4=C3C=CS4)CC2)C=C1 Chemical compound C1=CC=C(N2CCN(C3=NC=NC4=C3C=CS4)CC2)C=C1 DJBOBXSNRUYPEJ-UHFFFAOYSA-N 0.000 description 1
- DTVVYXHKICYNDP-UHFFFAOYSA-N C1=CN(CCCNC2=NC=NC3=C2C2=C(CCCCC2)S3)C=N1 Chemical compound C1=CN(CCCNC2=NC=NC3=C2C2=C(CCCCC2)S3)C=N1 DTVVYXHKICYNDP-UHFFFAOYSA-N 0.000 description 1
- UNVUOOZATZBTEM-UHFFFAOYSA-N C1=CN=C(N2CCN(C3=NC=NC4=C3C=CS4)CC2)N=C1 Chemical compound C1=CN=C(N2CCN(C3=NC=NC4=C3C=CS4)CC2)N=C1 UNVUOOZATZBTEM-UHFFFAOYSA-N 0.000 description 1
- GJBIRMDAEOGEAU-UHFFFAOYSA-N C1=CSC(N2CCN(C3=C4SC=CC4=NC=N3)CC2)=N1 Chemical compound C1=CSC(N2CCN(C3=C4SC=CC4=NC=N3)CC2)=N1 GJBIRMDAEOGEAU-UHFFFAOYSA-N 0.000 description 1
- RGUVBVAYJBKQDS-UHFFFAOYSA-N CC(=O)N1C2=C(C=CC=C2)NC2=C(C(=O)CC(C3=CC(Cl)=C(Cl)C=C3)C2)C1C1=CC=CN=C1 Chemical compound CC(=O)N1C2=C(C=CC=C2)NC2=C(C(=O)CC(C3=CC(Cl)=C(Cl)C=C3)C2)C1C1=CC=CN=C1 RGUVBVAYJBKQDS-UHFFFAOYSA-N 0.000 description 1
- ONYKRRVUHYDZCK-UHFFFAOYSA-N CC(=O)N1C2=C(C=CC=C2)NC2=C(C(=O)CC(C3=CC=C(C)C=C3)C2)C1C1=CN=CC=C1 Chemical compound CC(=O)N1C2=C(C=CC=C2)NC2=C(C(=O)CC(C3=CC=C(C)C=C3)C2)C1C1=CN=CC=C1 ONYKRRVUHYDZCK-UHFFFAOYSA-N 0.000 description 1
- MLASCQDFELZPIC-UHFFFAOYSA-N CC(=O)N1C2=CC=CC=C2NC2=C(C(=O)CC(C3=CC=C(C(C)(C)C)C=C3)C2)C1C1=CC=NC=C1 Chemical compound CC(=O)N1C2=CC=CC=C2NC2=C(C(=O)CC(C3=CC=C(C(C)(C)C)C=C3)C2)C1C1=CC=NC=C1 MLASCQDFELZPIC-UHFFFAOYSA-N 0.000 description 1
- DSTGDQDRPBCLJD-UHFFFAOYSA-N CC(C)C1=CC2=C(N3CCCN(C4=NCC(C)(C)S4)CC3)N=CN=C2S1 Chemical compound CC(C)C1=CC2=C(N3CCCN(C4=NCC(C)(C)S4)CC3)N=CN=C2S1 DSTGDQDRPBCLJD-UHFFFAOYSA-N 0.000 description 1
- ZTRYTDRHYCMFDJ-UHFFFAOYSA-N CC(C)C1=CC2=C(N3CCN(C4=NCC(C(F)(F)F)S4)CC3)N=CN=C2S1 Chemical compound CC(C)C1=CC2=C(N3CCN(C4=NCC(C(F)(F)F)S4)CC3)N=CN=C2S1 ZTRYTDRHYCMFDJ-UHFFFAOYSA-N 0.000 description 1
- FUGQNAUKABUDQI-UHFFFAOYSA-N CC(C)C1=CC2=C(N3CCN(C4=NCC(C)(C)S4)CC3)N=CN=C2S1 Chemical compound CC(C)C1=CC2=C(N3CCN(C4=NCC(C)(C)S4)CC3)N=CN=C2S1 FUGQNAUKABUDQI-UHFFFAOYSA-N 0.000 description 1
- ZKDOIQKOFWBGGZ-UHFFFAOYSA-N CC1(C)CC(=O)C2=C(C1)NC1=CC=CC=C1CC2C1=C/C2=C(\C=C/1)OCO2 Chemical compound CC1(C)CC(=O)C2=C(C1)NC1=CC=CC=C1CC2C1=C/C2=C(\C=C/1)OCO2 ZKDOIQKOFWBGGZ-UHFFFAOYSA-N 0.000 description 1
- PQDVHMZQUVCNOP-UHFFFAOYSA-N CC1(C)CN=C(N2CCN(C3=C4C(C5=CC=C(Cl)C=C5)=CSC4=NC=N3)CC2)S1 Chemical compound CC1(C)CN=C(N2CCN(C3=C4C(C5=CC=C(Cl)C=C5)=CSC4=NC=N3)CC2)S1 PQDVHMZQUVCNOP-UHFFFAOYSA-N 0.000 description 1
- MJMGSXKLOIRJBH-UHFFFAOYSA-N CC1(C)CN=C(N2CCN(C3=C4C=C(Br)SC4=NC=N3)CC2)S1 Chemical compound CC1(C)CN=C(N2CCN(C3=C4C=C(Br)SC4=NC=N3)CC2)S1 MJMGSXKLOIRJBH-UHFFFAOYSA-N 0.000 description 1
- MNSXQGKLDTVOLP-UHFFFAOYSA-N CC1(C)CN=C(N2CCN(C3=NC=NC4=C3C3=C(CCCC3)S4)CC2)S1 Chemical compound CC1(C)CN=C(N2CCN(C3=NC=NC4=C3C3=C(CCCC3)S4)CC2)S1 MNSXQGKLDTVOLP-UHFFFAOYSA-N 0.000 description 1
- CGRZMNFYFYJXES-UHFFFAOYSA-N CC1=C(C)C2=C(NC3CCN(CC4=CC=CC=C4)CC3)N=CN=C2S1 Chemical compound CC1=C(C)C2=C(NC3CCN(CC4=CC=CC=C4)CC3)N=CN=C2S1 CGRZMNFYFYJXES-UHFFFAOYSA-N 0.000 description 1
- RPKQZNFDISSLSN-UHFFFAOYSA-N CC1=C(C2=CC=CC=C2)SC2=C1C(N1CCN(C3=NC=CS3)CC1)=NC=N2 Chemical compound CC1=C(C2=CC=CC=C2)SC2=C1C(N1CCN(C3=NC=CS3)CC1)=NC=N2 RPKQZNFDISSLSN-UHFFFAOYSA-N 0.000 description 1
- LOVJXYZMJIJBIC-UHFFFAOYSA-N CC1=CC2=C(N3CCN(C4=NC=CC=C4)CC3)N=CN=C2S1 Chemical compound CC1=CC2=C(N3CCN(C4=NC=CC=C4)CC3)N=CN=C2S1 LOVJXYZMJIJBIC-UHFFFAOYSA-N 0.000 description 1
- ZHKHLFMPMIZCJG-UHFFFAOYSA-N CC1=CC2=C(N3CCN(C4=NC=CC=N4)CC3)N=CN=C2S1 Chemical compound CC1=CC2=C(N3CCN(C4=NC=CC=N4)CC3)N=CN=C2S1 ZHKHLFMPMIZCJG-UHFFFAOYSA-N 0.000 description 1
- UXHYZHVZGBVCBD-UHFFFAOYSA-N CC1=CC2=C(N3CCN(C4=NC=CS4)CC3)N=CN=C2S1 Chemical compound CC1=CC2=C(N3CCN(C4=NC=CS4)CC3)N=CN=C2S1 UXHYZHVZGBVCBD-UHFFFAOYSA-N 0.000 description 1
- YMIOTIXPIJQHKO-UHFFFAOYSA-N CC1=CC=CC=C1CC(=O)CC1=NC(C2=CC=C(F)C=C2)=CS1 Chemical compound CC1=CC=CC=C1CC(=O)CC1=NC(C2=CC=C(F)C=C2)=CS1 YMIOTIXPIJQHKO-UHFFFAOYSA-N 0.000 description 1
- RIBLLRWDYPFXIS-UHFFFAOYSA-N CC1=CSC(N2CCN(C3=NC(C)=NC4=C3C3=C(CCCC3)S4)CC2)=N1 Chemical compound CC1=CSC(N2CCN(C3=NC(C)=NC4=C3C3=C(CCCC3)S4)CC2)=N1 RIBLLRWDYPFXIS-UHFFFAOYSA-N 0.000 description 1
- SVFXTPMOKNXMBF-UHFFFAOYSA-N CC1=CSC(N2CCN(C3=NC(CN4CCOCC4)=NC4=C3C3=C(CC(C)CC3)S4)CC2)=N1 Chemical compound CC1=CSC(N2CCN(C3=NC(CN4CCOCC4)=NC4=C3C3=C(CC(C)CC3)S4)CC2)=N1 SVFXTPMOKNXMBF-UHFFFAOYSA-N 0.000 description 1
- IHPOVUXVIZRYAC-UHFFFAOYSA-N CC1=NN(C2=CC=CC=C2)N=C1C(N)=O Chemical compound CC1=NN(C2=CC=CC=C2)N=C1C(N)=O IHPOVUXVIZRYAC-UHFFFAOYSA-N 0.000 description 1
- TXLAORUTHAAZMG-UHFFFAOYSA-N CCC1=CC2=C(N3CCCN(C4=NCC(C)(C)S4)CC3)N=CN=C2S1.Cl Chemical compound CCC1=CC2=C(N3CCCN(C4=NCC(C)(C)S4)CC3)N=CN=C2S1.Cl TXLAORUTHAAZMG-UHFFFAOYSA-N 0.000 description 1
- DNMFXCFQKVVALR-UHFFFAOYSA-N CCC1=CC2=C(N3CCCN(CC(=O)N4CCCC4)CC3)N=CN=C2S1 Chemical compound CCC1=CC2=C(N3CCCN(CC(=O)N4CCCC4)CC3)N=CN=C2S1 DNMFXCFQKVVALR-UHFFFAOYSA-N 0.000 description 1
- YSZRMVPNQGZBKY-UHFFFAOYSA-N CCC1=CC2=C(N3CCN(C(=O)C4=CC=CC=C4)CC3)N=CN=C2S1 Chemical compound CCC1=CC2=C(N3CCN(C(=O)C4=CC=CC=C4)CC3)N=CN=C2S1 YSZRMVPNQGZBKY-UHFFFAOYSA-N 0.000 description 1
- GWNIGANSXBNWNV-UHFFFAOYSA-N CCC1=CC2=C(N3CCN(C(=O)C4=CC=CO4)CC3)N=CN=C2S1 Chemical compound CCC1=CC2=C(N3CCN(C(=O)C4=CC=CO4)CC3)N=CN=C2S1 GWNIGANSXBNWNV-UHFFFAOYSA-N 0.000 description 1
- ZAYUCMVNISSUTM-UHFFFAOYSA-N CCC1=CC2=C(N3CCN(C)CC3)N=CN=C2S1.Cl.Cl Chemical compound CCC1=CC2=C(N3CCN(C)CC3)N=CN=C2S1.Cl.Cl ZAYUCMVNISSUTM-UHFFFAOYSA-N 0.000 description 1
- KGADSAGDWSKRGE-UHFFFAOYSA-N CCC1=CC2=C(N3CCN(C4=NC=CC=C4)CC3)N=CN=C2S1.Cl.Cl Chemical compound CCC1=CC2=C(N3CCN(C4=NC=CC=C4)CC3)N=CN=C2S1.Cl.Cl KGADSAGDWSKRGE-UHFFFAOYSA-N 0.000 description 1
- PLPPLEOZEGMVKB-UHFFFAOYSA-N CCC1=CC2=C(N3CCN(C4=NCC(C)(C)S4)CC3)N=CN=C2S1.Cl Chemical compound CCC1=CC2=C(N3CCN(C4=NCC(C)(C)S4)CC3)N=CN=C2S1.Cl PLPPLEOZEGMVKB-UHFFFAOYSA-N 0.000 description 1
- KRHNUCOENKRGON-UHFFFAOYSA-N CCC1=CC2=C(N3CCN(C4=NN=C(C(F)(F)F)S4)CC3)N=CN=C2S1.Cl Chemical compound CCC1=CC2=C(N3CCN(C4=NN=C(C(F)(F)F)S4)CC3)N=CN=C2S1.Cl KRHNUCOENKRGON-UHFFFAOYSA-N 0.000 description 1
- DHKNVMARWYPUJF-UHFFFAOYSA-N CCC1=CC2=C(N3CCN(C4=NN=C(CC)S4)CC3)N=CN=C2S1 Chemical compound CCC1=CC2=C(N3CCN(C4=NN=C(CC)S4)CC3)N=CN=C2S1 DHKNVMARWYPUJF-UHFFFAOYSA-N 0.000 description 1
- CYCVICMTFWYLRA-UHFFFAOYSA-N CCC1=CC2=C(N3CCN(CC(=O)N4CCN(C)CC4)CC3)N=CN=C2S1 Chemical compound CCC1=CC2=C(N3CCN(CC(=O)N4CCN(C)CC4)CC3)N=CN=C2S1 CYCVICMTFWYLRA-UHFFFAOYSA-N 0.000 description 1
- LTVSNYBEXOGXQA-UHFFFAOYSA-N CCC1=CC2=C(N3CCN(CC(=O)N4CCOCC4)CC3)N=CN=C2S1 Chemical compound CCC1=CC2=C(N3CCN(CC(=O)N4CCOCC4)CC3)N=CN=C2S1 LTVSNYBEXOGXQA-UHFFFAOYSA-N 0.000 description 1
- WLMKLKVMNYSQDC-UHFFFAOYSA-N CCC1=CC2=C(N3CCN(CC4=CC=C(Cl)C=C4)CC3)N=CN=C2S1 Chemical compound CCC1=CC2=C(N3CCN(CC4=CC=C(Cl)C=C4)CC3)N=CN=C2S1 WLMKLKVMNYSQDC-UHFFFAOYSA-N 0.000 description 1
- HSOAGWHNYSIYIJ-UHFFFAOYSA-N CCC1=CC2=C(N=CN=C2N2CCN(C3=NC=CC=N3)CC2)S1 Chemical compound CCC1=CC2=C(N=CN=C2N2CCN(C3=NC=CC=N3)CC2)S1 HSOAGWHNYSIYIJ-UHFFFAOYSA-N 0.000 description 1
- OSVPUNIFECUWFC-UHFFFAOYSA-N CCC1=CC2=C(N=CN=C2N2CCN(CC3=CC=CC=C3)CC2)S1 Chemical compound CCC1=CC2=C(N=CN=C2N2CCN(CC3=CC=CC=C3)CC2)S1 OSVPUNIFECUWFC-UHFFFAOYSA-N 0.000 description 1
- SYDLODZYNCJFKZ-UHFFFAOYSA-N CCC1=CC2=C(NC3CCN(CC4=CC=CC=C4)CC3)N=CN=C2S1 Chemical compound CCC1=CC2=C(NC3CCN(CC4=CC=CC=C4)CC3)N=CN=C2S1 SYDLODZYNCJFKZ-UHFFFAOYSA-N 0.000 description 1
- VFDPHQYGOSRWQJ-UHFFFAOYSA-N CCC1=CC2=C(NCC3CCN(CC4=CC=C(F)C=C4)CC3)N=CN=C2S1 Chemical compound CCC1=CC2=C(NCC3CCN(CC4=CC=C(F)C=C4)CC3)N=CN=C2S1 VFDPHQYGOSRWQJ-UHFFFAOYSA-N 0.000 description 1
- QSYPZBWUQBHLFI-UHFFFAOYSA-N CCC1=CC2=C(NCCN(CC)CC3=CC=CC=C3)N=CN=C2S1 Chemical compound CCC1=CC2=C(NCCN(CC)CC3=CC=CC=C3)N=CN=C2S1 QSYPZBWUQBHLFI-UHFFFAOYSA-N 0.000 description 1
- ZHUGHCGXPYULEG-UHFFFAOYSA-N CCOC(=O)C1=C(C)C2=C(N=C(CN3CCOCC3)N=C2N2CCN(C3=NC=CS3)CC2)S1 Chemical compound CCOC(=O)C1=C(C)C2=C(N=C(CN3CCOCC3)N=C2N2CCN(C3=NC=CS3)CC2)S1 ZHUGHCGXPYULEG-UHFFFAOYSA-N 0.000 description 1
- OLPKXXCSCHAUBL-UHFFFAOYSA-N CN1CCN(C2=NC=NC3=C2C(C2=CC=CC=C2)=C(C2=CC=CC=C2)O3)CC1 Chemical compound CN1CCN(C2=NC=NC3=C2C(C2=CC=CC=C2)=C(C2=CC=CC=C2)O3)CC1 OLPKXXCSCHAUBL-UHFFFAOYSA-N 0.000 description 1
- ATWLLBLEYULTQR-UHFFFAOYSA-N COC(=O)CC1=NC(C2CCCCC2)=CS1 Chemical compound COC(=O)CC1=NC(C2CCCCC2)=CS1 ATWLLBLEYULTQR-UHFFFAOYSA-N 0.000 description 1
- UVKVYJNUIDQHMO-UHFFFAOYSA-N COC1=C(O)C=CC(C2CC3=CC=CC=C3NC3=C2C(=O)CCC3)=C1 Chemical compound COC1=C(O)C=CC(C2CC3=CC=CC=C3NC3=C2C(=O)CCC3)=C1 UVKVYJNUIDQHMO-UHFFFAOYSA-N 0.000 description 1
- ZHZKSJUDMIUMPI-UHFFFAOYSA-N COC1=C(OC)C=C(C2CC(=O)C3=C(CC4=CC=CC=C4NC3C3=C(C)C=CC=C3)C2)C=C1 Chemical compound COC1=C(OC)C=C(C2CC(=O)C3=C(CC4=CC=CC=C4NC3C3=C(C)C=CC=C3)C2)C=C1 ZHZKSJUDMIUMPI-UHFFFAOYSA-N 0.000 description 1
- FTFKENGXVNLZSM-UHFFFAOYSA-N COC1=C(OC)C=C(C2CC(=O)C3=C(CC4=CC=CC=C4NC3C3=CC=CN=C3)C2)C=C1 Chemical compound COC1=C(OC)C=C(C2CC(=O)C3=C(CC4=CC=CC=C4NC3C3=CC=CN=C3)C2)C=C1 FTFKENGXVNLZSM-UHFFFAOYSA-N 0.000 description 1
- WGEAGVYBJFKZNL-UHFFFAOYSA-N COC1=CC(C2CC(=O)C3=C(CC4=CC=CC=C4NC3C3=CC=NC=C3)C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2CC(=O)C3=C(CC4=CC=CC=C4NC3C3=CC=NC=C3)C2)=CC(OC)=C1OC WGEAGVYBJFKZNL-UHFFFAOYSA-N 0.000 description 1
- NVAWSQVMJQDOIG-UHFFFAOYSA-N COC1=CC(C2CC3=CC=CC=C3NC3=C2C(=O)CC(C)(C)C3)=CC(OC)=C1OC Chemical compound COC1=CC(C2CC3=CC=CC=C3NC3=C2C(=O)CC(C)(C)C3)=CC(OC)=C1OC NVAWSQVMJQDOIG-UHFFFAOYSA-N 0.000 description 1
- AQWKNAJFSBSHCZ-UHFFFAOYSA-N COC1=CC=C(C2=CSC(CC(N)=O)=N2)C=C1 Chemical compound COC1=CC=C(C2=CSC(CC(N)=O)=N2)C=C1 AQWKNAJFSBSHCZ-UHFFFAOYSA-N 0.000 description 1
- VQEAGRYMZHFYAX-UHFFFAOYSA-N COC1=CC=C(C2CC(=O)C3=C(C2)NC2=C(C=CC=C2)N(C(C)=O)C3C2=CC=CN=C2)C=C1 Chemical compound COC1=CC=C(C2CC(=O)C3=C(C2)NC2=C(C=CC=C2)N(C(C)=O)C3C2=CC=CN=C2)C=C1 VQEAGRYMZHFYAX-UHFFFAOYSA-N 0.000 description 1
- XZKJXUGWCBNBMM-UHFFFAOYSA-N COC1=CC=C(CN2CCCN(C3=C4C(=NC=N3)SC(C)=C4C)CC2)C=C1 Chemical compound COC1=CC=C(CN2CCCN(C3=C4C(=NC=N3)SC(C)=C4C)CC2)C=C1 XZKJXUGWCBNBMM-UHFFFAOYSA-N 0.000 description 1
- UKEVYWZXESQHLG-UHFFFAOYSA-N Cc(cccc1)c1NC(Cc1nc(-c(cc2)ccc2F)c[s]1)=O Chemical compound Cc(cccc1)c1NC(Cc1nc(-c(cc2)ccc2F)c[s]1)=O UKEVYWZXESQHLG-UHFFFAOYSA-N 0.000 description 1
- PWWCETJFNDFBPM-UHFFFAOYSA-N FC1=CC=C(C2=CSC3=NC=NC(N4CCN(C5=NC=CS5)CC4)=C23)C=C1 Chemical compound FC1=CC=C(C2=CSC3=NC=NC(N4CCN(C5=NC=CS5)CC4)=C23)C=C1 PWWCETJFNDFBPM-UHFFFAOYSA-N 0.000 description 1
- GXDBXDJTVFKURZ-UHFFFAOYSA-N NC(=O)CC1=NC(C2=CC=C(F)C=C2)=CS1 Chemical compound NC(=O)CC1=NC(C2=CC=C(F)C=C2)=CS1 GXDBXDJTVFKURZ-UHFFFAOYSA-N 0.000 description 1
- MITSOTISLAVGFW-UHFFFAOYSA-N NC(=O)CC1=NC(C2=CC=CC=C2)=CS1 Chemical compound NC(=O)CC1=NC(C2=CC=CC=C2)=CS1 MITSOTISLAVGFW-UHFFFAOYSA-N 0.000 description 1
- YTJQJGKMRLQBJP-UHFFFAOYSA-N NC1=CC(C2=CC=CN=C2)=CC=C1 Chemical compound NC1=CC(C2=CC=CN=C2)=CC=C1 YTJQJGKMRLQBJP-UHFFFAOYSA-N 0.000 description 1
- ZERNLALKKMJGGZ-UHFFFAOYSA-N O=C1CC(C2=CC3=C(C=C2)OCO3)CC2=C1C(C1=CC=CN=C1)NC1=CC=CC=C1C2 Chemical compound O=C1CC(C2=CC3=C(C=C2)OCO3)CC2=C1C(C1=CC=CN=C1)NC1=CC=CC=C1C2 ZERNLALKKMJGGZ-UHFFFAOYSA-N 0.000 description 1
- XZCJNDAPWYHICB-UHFFFAOYSA-N O=C1CC(C2=CC3=C(C=C2)OCO3)CC2=C1C(C1=CC=NC=C1)NC1=CC=CC=C1C2 Chemical compound O=C1CC(C2=CC3=C(C=C2)OCO3)CC2=C1C(C1=CC=NC=C1)NC1=CC=CC=C1C2 XZCJNDAPWYHICB-UHFFFAOYSA-N 0.000 description 1
- JTQRRRUVWBLIFL-UHFFFAOYSA-N OCC1=CC=C(C2=CC=NC=C2)C=C1 Chemical compound OCC1=CC=C(C2=CC=NC=C2)C=C1 JTQRRRUVWBLIFL-UHFFFAOYSA-N 0.000 description 1
- LARHSXAPRRVZBC-UHFFFAOYSA-N [H]C1(C)CCN(C2=NC=NC3=C2C=CS3)CC1 Chemical compound [H]C1(C)CCN(C2=NC=NC3=C2C=CS3)CC1 LARHSXAPRRVZBC-UHFFFAOYSA-N 0.000 description 1
- SNMBMZLFDKOUQN-UHFFFAOYSA-N [H]N(C1=NC=NC2=C1C1=C(CC(C)CC1)S2)C1CCN(CC2=CC=CC=C2)CC1 Chemical compound [H]N(C1=NC=NC2=C1C1=C(CC(C)CC1)S2)C1CCN(CC2=CC=CC=C2)CC1 SNMBMZLFDKOUQN-UHFFFAOYSA-N 0.000 description 1
- FQZXDFIVXYTGKE-UHFFFAOYSA-N [H]N(C1=NC=NC2=C1C1=C(CCC1)S2)C1CCN(CC2=CC=CC=C2)CC1 Chemical compound [H]N(C1=NC=NC2=C1C1=C(CCC1)S2)C1CCN(CC2=CC=CC=C2)CC1 FQZXDFIVXYTGKE-UHFFFAOYSA-N 0.000 description 1
- QENLTPYLVKZTGX-UHFFFAOYSA-N [H]N(CC)(CC)CC1=NC2=C(C(N3CCN(C4=NC=CS4)CC3)=N1)C(C)=C(C)S2 Chemical compound [H]N(CC)(CC)CC1=NC2=C(C(N3CCN(C4=NC=CS4)CC3)=N1)C(C)=C(C)S2 QENLTPYLVKZTGX-UHFFFAOYSA-N 0.000 description 1
- CCPUMOUKBIRFHT-UHFFFAOYSA-N [H]N(CC1=CC=CC=C1)C(=O)CC1=NC(C2=CC=C(F)C=C2)=CS1 Chemical compound [H]N(CC1=CC=CC=C1)C(=O)CC1=NC(C2=CC=C(F)C=C2)=CS1 CCPUMOUKBIRFHT-UHFFFAOYSA-N 0.000 description 1
- GSIBSMJFTKMTCI-UHFFFAOYSA-N [H]N([H])C(=O)CC1=NC(C2=C(C)C=C(C)C(C)=C2)=CS1 Chemical compound [H]N([H])C(=O)CC1=NC(C2=C(C)C=C(C)C(C)=C2)=CS1 GSIBSMJFTKMTCI-UHFFFAOYSA-N 0.000 description 1
- PRRYDJJPKDVUGE-UHFFFAOYSA-N [H]N([H])C(=O)CC1=NC(C2=CC(Br)=C(OC)C=C2)=CS1 Chemical compound [H]N([H])C(=O)CC1=NC(C2=CC(Br)=C(OC)C=C2)=CS1 PRRYDJJPKDVUGE-UHFFFAOYSA-N 0.000 description 1
- ISQPFSWGGGAMRQ-UHFFFAOYSA-N [H]N([H])C(=O)CC1=NC(C2=CC(C)=C(C)C=C2)=CS1 Chemical compound [H]N([H])C(=O)CC1=NC(C2=CC(C)=C(C)C=C2)=CS1 ISQPFSWGGGAMRQ-UHFFFAOYSA-N 0.000 description 1
- RLOFEQQGBMPQSA-UHFFFAOYSA-N [H]N([H])C(=O)CC1=NC(C2=CC=C(Br)C=C2)=CS1 Chemical compound [H]N([H])C(=O)CC1=NC(C2=CC=C(Br)C=C2)=CS1 RLOFEQQGBMPQSA-UHFFFAOYSA-N 0.000 description 1
- GCQBRBAAQQEUFP-UHFFFAOYSA-N [H]N([H])C(=O)CC1=NC(C2=CC=C(N([H])C(=O)CCC)C=C2)=C(C)S1 Chemical compound [H]N([H])C(=O)CC1=NC(C2=CC=C(N([H])C(=O)CCC)C=C2)=C(C)S1 GCQBRBAAQQEUFP-UHFFFAOYSA-N 0.000 description 1
- ZIMSBVIBXGILPR-UHFFFAOYSA-N [H]N([H])C(=O)CC1=NC(C2=CC=CC(Br)=C2)=CS1 Chemical compound [H]N([H])C(=O)CC1=NC(C2=CC=CC(Br)=C2)=CS1 ZIMSBVIBXGILPR-UHFFFAOYSA-N 0.000 description 1
- CVMYBEQTEZYBPG-UHFFFAOYSA-N [H]N([H])C(=O)CC1=NC(C2=CC=CC(Cl)=C2)=CS1 Chemical compound [H]N([H])C(=O)CC1=NC(C2=CC=CC(Cl)=C2)=CS1 CVMYBEQTEZYBPG-UHFFFAOYSA-N 0.000 description 1
- OVSUXIKXBGCTIP-UHFFFAOYSA-N [H]N1(C)CCCN(C2=NC=NC3=C2C=CS3)CC1 Chemical compound [H]N1(C)CCCN(C2=NC=NC3=C2C=CS3)CC1 OVSUXIKXBGCTIP-UHFFFAOYSA-N 0.000 description 1
- YDOYCLXISQNIQJ-UHFFFAOYSA-N [H]N1(C)CCN(C2=NC=NC3=C2C=C(C)S3)CC1 Chemical compound [H]N1(C)CCN(C2=NC=NC3=C2C=C(C)S3)CC1 YDOYCLXISQNIQJ-UHFFFAOYSA-N 0.000 description 1
- ANJKDJUSDDDXQA-UHFFFAOYSA-N [H]N1(CC2=CC=CS2)CCN(C2=NC=NC3=C2C=CS3)CC1 Chemical compound [H]N1(CC2=CC=CS2)CCN(C2=NC=NC3=C2C=CS3)CC1 ANJKDJUSDDDXQA-UHFFFAOYSA-N 0.000 description 1
- KZNONBBYBWMIGN-UHFFFAOYSA-N [H]N1([H])CCN(C2=NC=NC3=C2C2=C(CCCC2)S3)CC1 Chemical compound [H]N1([H])CCN(C2=NC=NC3=C2C2=C(CCCC2)S3)CC1 KZNONBBYBWMIGN-UHFFFAOYSA-N 0.000 description 1
- NIKURXFTGUGNBG-UHFFFAOYSA-N [H]N1([H])CCN(C2=NC=NC3=C2C=CS3)CC1 Chemical compound [H]N1([H])CCN(C2=NC=NC3=C2C=CS3)CC1 NIKURXFTGUGNBG-UHFFFAOYSA-N 0.000 description 1
- PEEICNZLYTUQLE-UHFFFAOYSA-N [H]N1=CC=CC=C1N1CCN(C2=NC=NC3=C2C=CS3)CC1 Chemical compound [H]N1=CC=CC=C1N1CCN(C2=NC=NC3=C2C=CS3)CC1 PEEICNZLYTUQLE-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates generally to treatment of leukemia.
- the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion oncoproteins, as well as systems and methods to screen for such compositions.
- Fusion of MLL with one of 60 partner genes forms a chimeric oncogene which upregulates HOX genes resulting in a blockage of blood cell differentiation that ultimately leads to acute leukemia (Eguchi et al. Int J Hematol., 2003. 78(5): p. 390-401, herein incorporated by reference in its entirety).
- Patients with leukemias harboring MLL translocations have a very poor prognosis (35% five year survival) and it is clear that novel therapeutic strategies are urgently needed to treat these leukemias (Slang. Hematol Oncol., 2005. 23(1): p. 1-9, herein incorporated by reference in its entirety).
- Menin is a critical cofactor in MLL-associated leukemias.
- Menin is a tumor-suppressor protein encoded by the Multiple Endocrine Neoplasia (MEN) gene.
- MEN Multiple Endocrine Neoplasia
- Menin is a ubiquitously expressed nuclear protein that is engaged in interactions with a cohort of transcription factors, chromatin modifying proteins, and DNA processing and repair proteins (Agarwal et al. Horm Metab Res., 2005. 37(6): p. 369-74, herein incorporated by reference in its entirety).
- the biological function of menin remains unclear and is context dependent. It functions as a tumor suppressor in endocrine organs (Marx. Nat Rev Cancer., 2005. 5(5): p. 367-75, herein incorporated by reference in its entirety) but has an oncogenic role in myeloid cells (Yokoyama et al., Cell., 2005.
- MLL fusion oncoproteins The leukemogenic activity of MLL fusion oncoproteins is dependent on association with menin. Therefore, selective targeting of this interaction could provide an attractive therapeutic approach to develop novel drugs for the MLL-related leukemias.
- the present invention provides compositions for the treatment of leukemia which inhibit binding of one or more MLL fusion proteins to menin and/or MLL wild type to menin.
- the composition comprises a thienopyrimidine class compound.
- the thienopyrimidine class compound is of the general formula or pharmaceutically acceptable salts of thereof:
- R1, R2, R3, R4, R5, R6, R7, and R8 independently comprise: H, alkyl (e.g., methyl, ethyl, etc.) which might be further substituted or non-substituted, alkoxy further substituted or non-substituted, a halogen (e.g.
- a ketone a carbocyclic ring, an aromatic ring, a heterocyclic aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, a heterocyclic non-aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic aromatic or non-aromatic ring attached or fused to the thienopyrimidine ring system non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic or heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members fused to another aromatic ring, or a hydrogen bond donor or a hydrogen bond accept
- Z is S or O or NH or CH—CH.
- X and Y are each independently N or C;
- the present invention comprises any substituent that results in compounds inhibiting the interaction of menin with MLL and/or MLL fusion proteins that can be used to treat or prevent leukemia.
- the thienopyrimidine class compound is of the general formula or pharmaceutically acceptable salts of thereof:
- the thienopyrimidine class compound has the structure:
- the thienopyrimidine class compound is selected from Compounds 1-31 and 60-83.
- the composition comprises any structural analogues of compositions 1-31 and 60-83.
- the composition comprises a benzodiazepine class compound.
- the benzodiazepine class compound is of the general formula or pharmaceutically acceptable salts of thereof:
- R1, R2, R3, and R4 independently comprise: H, alkyl which might be substituted or non-substituted, acetyl, alkoxy, a halogen (e.g. F, Cl, Br, I, and At), a ketone, a carbocyclic ring, an aromatic ring, a heterocyclic aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, a heterocyclic non-aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic aromatic or non-aromatic ring fused or attached to the benzodiazepine ring system non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or
- the benzodiazepine class compound has the structure:
- the benzodiazepine class compound is selected from: Compounds 32-41 and 84-86.
- compositions comprise structures of Compounds 42-59 or derivatives there.
- compositions comprise any structural analogues of compositions 35-41 and 84-86.
- compositions may comprise combinations of any of the above compounds with one another or with other compounds of interest. Stereoisomers, salts, and derivates of the compounds are further contemplated.
- the present invention provides a method comprising: administering a composition for the treatment of leukemia (e.g., which inhibits binding of one or more MLL fusion proteins to menin or MLL wild type to menin) to a subject suffering from leukemia.
- leukemia e.g., which inhibits binding of one or more MLL fusion proteins to menin or MLL wild type to menin
- the leukemia comprises AML or ALL.
- the composition comprises a thienopyrimidine class compound.
- the composition comprises a benzodiazepine class compound.
- the composition comprises compounds 42-59 and their analogues.
- the present invention provides a method of screening compounds effective in treating leukemia comprising assaying one or more compounds for inhibition of the interaction between MLL and menin.
- the screening is performed in vitro.
- the screening is performed in vivo.
- the assaying comprises a fluorescence polarization assay.
- the assaying comprises a time-resolved fluorescence resonance energy transfer assay.
- the assaying comprises a nuclear magnetic resonance assay.
- the assaying comprises cellular assays and mice studies.
- the present invention provides a method of inhibiting the interaction of MLL and menin comprising: (a) providing: (i) a sample comprising MLL and menin and (ii) a composition configured to inhibit the interaction of MLL and menin, (b) administering the composition to the sample, (c) contacting MLL and/or menin with the composition, and (d) inhibiting the interaction between MLL and menin, and between MLL fusion proteins and menin.
- the sample comprises cells from a subject suffering from leukemia.
- the subject is a human subject or a human patient.
- the cells are within a subject suffering from leukemia.
- the composition comprises a thienopyrimidine class compound.
- the composition comprises a benzodiazepine class compound.
- the composition comprises compounds 42-59 and their analogues.
- the present invention comprises any structural analogues of Compounds 1-86.
- FIGS. 1A-B A. Binding of Compound 1 (labeled as CCG21397; thienopyrimidine class) to menin demonstrated in STD (saturation transfer difference) experiment measured for 80 ⁇ M of Compound 1 and 2.5 ⁇ M menin: reference 1D spectrum (black) showing separately aromatic and aliphatic regions; STD spectrum (red) showing binding of Compound 1 to menin; competition STD spectrum (blue) showing the decrease of STD effect in the presence of 25 ⁇ M MLL peptide, which confirms specific binding of Compound 1 to menin. The H and CH 3 signals from the ligand shown on the spectra are labeled on the structure. B.
- Signals from the ligand's methyl groups are labeled M1, M2 and M1′, M2′ (two sets of peaks are from different stereoisomers). The intensity of peak corresponding to impurity (labeled with asterix) is not affected by addition of MLL.
- B. MTT viability assay for the most potent thienopyrimidine compound (AS-1-19 Compound 70) in human leukemia cell lines with MLL translocations (MV4;11 harboring MLL-AF4 fusion and MonoMac6 harboring MLL-AF9 fusion protein).
- MI-2-12 Compound 86
- MTT viability assay for the most potent benzodiazepine compound (MI-2-12 Compound 86) in human leukemia cell lines with MLL translocations (MV4;11 harboring MLL-AF4 fusion and MonoMac6 harboring MLL-AF9 fusion protein).
- C. MTT cell viability assay with the most potent benzodiazepine compound (Compounds 86 MI-2-12) in non-MLL leukemia cell lines (Kasumi-1 and ME-1) showing no or very limited effect on cell growth.
- FIG. 12 Determination of IC 50 by NMR spectroscopy.
- system refers a group of objects, compounds, methods, and/or devices that form a network for performing a desired objective.
- sample refers to anything capable of being subjected to the compositions and methods provided herein.
- the sample may be in vitro or in vivo.
- samples are “mixture” samples, which samples from more than one subject or individual.
- the methods provided herein comprise purifying or isolating the sample.
- the sample is purified or unpurified protein.
- a sample may be from a clinical or research setting.
- a sample may comprise cells, fluids (e.g. blood, urine, cytoplasm, etc.), tissues, organs, lysed cells, whole organisms, etc.
- a sample may be derived from a subject.
- a sample may comprise one or more partial or whole subjects.
- the term “subject” refers to any animal including, but not limited to, insects, humans, non-human primates, vertebrates, bovines, equines, felines, canines, pigs, rodents (e.g., mice), and the like.
- the terms “subject” and “patient” may be used interchangeably, wherein the term “patient” generally refers to a subject seeking or receiving treatment or preventative measures from a clinician or health care provider.
- a subject may be of any stage of life (e.g. embryo, fetus, infant, neonatal, child, adult, live, dead, etc.).
- the term “subject at risk for cancer” refers to a subject with one or more risk factors for developing a specific cancer.
- Risk factors include, but are not limited to, gender, age, genetic predisposition, environmental exposure, and previous incidents of cancer, preexisting non-cancer diseases, and lifestyle.
- the term “characterizing cancer in subject” refers to the identification of one or more properties of a cancer sample in a subject, including but not limited to, the presence of benign, pre-cancerous or cancerous tissue or cells and the stage of the cancer. Cancers may be characterized by identifying cancer cells with the compositions and methods of the present invention.
- test compound and “candidate compound” refer to any chemical entity, pharmaceutical, drug, and the like that is a candidate for use to treat or prevent a disease, illness, sickness, or disorder of bodily function (e.g., cancer).
- Test compounds comprise both known and potential therapeutic compounds.
- a test compound can be determined to be therapeutic by screening using the screening methods of the present invention.
- an effective amount refers to the amount of a compound (e.g., a compound having a structure presented above or elsewhere described herein) sufficient to effect beneficial or desired results.
- An effective amount can be administered in one or more administrations, applications or dosages and is not limited to or intended to be limited to a particular formulation or administration route.
- co-administration refers to the administration of at least two agent(s) (e.g., a compound having a structure presented above or elsewhere described herein) or therapies to a subject. In some embodiments, the co-administration of two or more agents/therapies is concurrent. In other embodiments, a first agent/therapy is administered prior to a second agent/therapy.
- a first agent/therapy is administered prior to a second agent/therapy.
- the appropriate dosage for co-administration can be readily determined by one skilled in the art. In some embodiments, when agents/therapies are co-administered, the respective agents/therapies are administered at lower dosages than appropriate for their administration alone. Thus, co-administration is especially desirable in embodiments where the co-administration of the agents/therapies lowers the requisite dosage of a known potentially harmful (e.g., toxic) agent(s).
- composition refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo, in vivo or ex vivo.
- the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents.
- the compositions also can include stabilizers and preservatives.
- stabilizers and adjuvants See e.g., Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, Pa. [1975]).
- the term “pharmaceutically acceptable salt” refers to any pharmaceutically acceptable salt (e.g., acid or base) of a compound of the present invention which, upon administration to a subject, is capable of providing a compound of this invention or an active metabolite or residue thereof.
- salts of the compounds of the present invention may be derived from inorganic or organic acids and bases.
- acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like.
- Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
- bases include, but are not limited to, alkali metals (e.g., sodium) hydroxides, alkaline earth metals (e.g., magnesium), hydroxides, ammonia, and compounds of formula NW 4 + , wherein W is C 1-4 alkyl, and the like.
- salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate,
- salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable.
- salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
- the term “instructions for administering said compound to a subject,” and grammatical equivalents thereof, includes instructions for using the compositions contained in a kit for the treatment of conditions characterized by viral infection (e.g., providing dosing, route of administration, decision trees for treating physicians for correlating patient-specific characteristics with therapeutic courses of action).
- the compounds of the present invention e.g. as shown in structures above and elsewhere presented herein
- can be packaged into a kit which may include instructions for administering the compounds to a subject.
- the present invention provides compositions and methods for prevention and/or treatment of leukemia (e.g. MLL-related leukemia and other acute leukemias).
- the present invention provides compositions and method for the inhibition of the protein-protein interaction between menin and MLL fusion proteins and/or menin and MLL wild type protein.
- compositions and methods inhibit the interaction that is important for the oncogenic (e.g. leukemogenic) potential of MLL fusions.
- the present invention provides small molecule inhibitors of interactions between menin and MLL fusion proteins and/or menin and MLL wild type protein.
- compositions and methods reverse (e.g.
- compositions find utility in targeted therapies (e.g. anti-leukemia agents).
- compounds block menin-MLL interactions.
- the present invention provides compositions which inhibit the interaction between MLL (e.g. MLL fusion proteins and MLL wild type) and menin.
- MLL e.g. MLL fusion proteins and MLL wild type
- any compounds, small molecules (e.g. pharmaceuticals, drugs, drug-like molecules, etc.), macromolecules (e.g. peptides, nucleic acids, etc.) and/or macromolecular complexes which inhibit the MLL-menin interaction find utility in the present invention.
- the present invention provides small molecule compounds which inhibit MLL-menin interactions.
- compositions of the present invention decrease the affinity of menin for MLL (e.g. MLL fusion proteins) and/or MLL (e.g. MLL wild type protein) for menin.
- compositions of the present invention disrupt bonding (e.g. hydrogen bonding, ionic bonding, covalent bonding, etc.), molecular interactions (e.g. hydrophobic interactions, electrostatic interactions, van der Waals interactions, etc.), shape recognition, and/or molecular recognition between MLL (e.g. MLL fusion proteins or MLL wild type protein) and menin.
- bonding e.g. hydrogen bonding, ionic bonding, covalent bonding, etc.
- molecular interactions e.g. hydrophobic interactions, electrostatic interactions, van der Waals interactions, etc.
- shape recognition e.g. MLL fusion proteins or MLL wild type protein
- the present invention provides any small molecules or classes of small molecules which disrupt, target, or inhibit MLL/menin interactions; and/or treat/prevent leukemia.
- small molecules are effective in inhibiting the interaction of MLL-fusion proteins with menin or MLL wild type protein with menin.
- the present invention provides thienopyrimidine and benzodiazepine classes of small molecules.
- thienopyrimidine and benzodiazepine small molecules inhibit the interaction of MLL (e.g. MLL-fusion proteins or MLL wild type) with menin.
- thienopyrimidine and benzodiazepine small molecules inhibit the oncogenic (e.g.
- thienopyrimidine and benzodiazepine small molecules treat and/or prevent leukemia (e.g. MLL-dependant leukemias, MLL-related leukemias, or other leukemias with and without high level of Hox gene expression etc.).
- leukemia e.g. MLL-dependant leukemias, MLL-related leukemias, or other leukemias with and without high level of Hox gene expression etc.
- thienopyrimidine class small molecules are of the general structures:
- R1, R2 H, alkyl which might be substituted or non-substituted, alkoxy further substituted or non-substituted, a halogen (e.g.
- a carbocyclic aromatic ring a carbocyclic aromatic ring comprising six carbons, a carbocyclic non-aromatic ring, a carbocyclic non-aromatic ring of three to six carbons, a heterocyclic aromatic ring, a five or six member heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members, any aromatic or non-aromatic ring non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, a five or six member heterocyclic non-aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members, a carbocyclic aromatic or non-aromatic ring fused to the thienopyrimidine ring system, a five or six member carbocyclic aromatic or non-aromatic ring fused to the thienopyrimidine ring system, any aromatic or non-ar
- a carbocyclic aromatic ring comprising six carbons, a carbocyclic non-aromatic ring of three to six carbons, a five or six member heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members, a five or six member heterocyclic non-aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members, any aromatic or non-aromatic ring non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, a five or six member carbocyclic or heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members fused to another aromatic ring, a hydrogen bond donor or a hydrogen bond acceptor, etc.
- Z is S or O or NH or CH—CH.
- X and Y are each independently N or C;
- R1, R2, R3, and R4 comprise any substituents which result in compounds which inhibit the interaction of MLL-fusion proteins with menin and/or treat or prevent leukemia.
- thienopyrimidine class small molecules comprise the compositions of Tables 1 and 2, derivatives, combinations, pharmaceutically acceptable salts, and/or hydrates thereof.
- thienopyrimidine class small molecules inhibit the interaction of MLL (e.g. MLL fusion proteins) with menin.
- thienopyrimidine class small molecules reverse and/or inhibit the oncogenic (e.g. leukemogenic) effects of MLL-fusion proteins, and/or MLL/menin and MLL fusion proteins/menin interactions.
- thienopyrimidine class small molecules prevent or treat leukemia.
- benzodiazepine class small molecules are of the general structure:
- R1, R2, R3, R4 H, alkyl, acetyl, alkoxy, ketone, a halogen (e.g. F, Cl, Br, I, and At), a carbocyclic aromatic ring, a carbocyclic aromatic ring comprising six carbons, a carbocyclic non-aromatic ring, a carbocyclic non-aromatic ring of three to six carbons, a heterocyclic aromatic ring, a five or six member heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members, a heterocyclic non-aromatic ring, a five or six member heterocyclic non-aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members, a five or six member carbocyclic or heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members, a five or six member carbocyclic or heterocyclic aromatic ring comprising carbon atom
- R1, R2, R3, and R4 comprise any substituents which result in compounds which inhibit the interaction of MLL-fusion proteins with menin and/or treat or prevent leukemia.
- benzodiazepine class small molecules comprise the compositions of Table 3, derivatives, combinations, pharmaceutically acceptable salts, and/or hydrates thereof.
- benzodiazepine class small molecules inhibit the interaction of MLL (e.g. MLL fusion proteins or MLL wild type) with menin.
- benzodiazepine class small molecules reverse and/or inhibit the oncogenic (e.g. leukemogenic) effects of MLL, MLL-fusion proteins, and/or MLL/menin interactions.
- benzodiazepine class small molecules prevent or treat leukemia.
- the compound has the structure of Compounds 42-59, or derivatives thereof.
- the present invention provides administration of compositions of the present invention to subjects (e.g. leukemia patients) to treat or prevent disease (e.g. cancer, leukemia, MLL-related leukemia, etc.). In some embodiments, the present invention provides administration of compositions for the treatment or prevention of leukemia (e.g.
- lymphoblastic leukemias lymphocytic leukemias
- myeloid leukemias myelogenous leukemias
- Acute lymphoblastic leukemia ALL
- Chronic lymphocytic leukemia CLL
- Acute myelogenous leukemia AML
- Chronic myelogenous leukemia CML
- Hairy cell leukemia HCL
- T-PLL T-cell prolymphocytic leukemia
- Large granular lymphocytic leukemia MLL-positive leukemias, MLL-induced lukemias, etc.
- any of the above compounds is co-administered or used in combination with a known therapeutic agent (e.g., methotrexate, 6-mercaptopurine, antibody therapies, etc.).
- a known therapeutic agent e.g., methotrexate, 6-mercaptopurine, antibody therapies, etc.
- compositions of the present invention are provided as pharmaceutical and/or therapeutic compositions.
- the pharmaceutical and/or therapeutic compositions of the present invention can be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration can be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral.
- Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
- Compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional carriers; aqueous, powder, or oily bases; thickeners; and the like can be necessary or desirable.
- Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non aqueous media, capsules, sachets or tablets.
- compositions and formulations for parenteral, intrathecal or intraventricular administration can include sterile aqueous solutions that can also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.
- Pharmaceutical and/or therapeutic compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome containing formulations. These compositions can be generated from a variety of components that include, but are not limited to, preformed liquids, self emulsifying solids and self emulsifying semisolids.
- compositions of the present invention can be prepared according to conventional techniques well known in the pharmaceutical/nutriceutical industries. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
- the compositions of the present invention can be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas.
- compositions of the present invention can also be formulated as suspensions in aqueous, non aqueous, oil-based, or mixed media.
- Suspensions can further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran.
- the suspension can also contain stabilizers.
- the pharmaceutical compositions can be formulated and used as foams.
- Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product.
- Dosing and administration regimes are tailored by the clinician, or others skilled in the pharmacological arts, based upon well known pharmacological and therapeutic considerations including, but not limited to, the desired level of therapeutic effect, and the practical level of therapeutic effect obtainable. Generally, it is advisable to follow well-known pharmacological principles for administrating chemotherapeutic agents (e.g., it is generally advisable to not change dosages by more than 50% at time and no more than every 3-4 agent half-lives). For compositions that have relatively little or no dose-related toxicity considerations, and where maximum efficacy is desired, doses in excess of the average required dose are not uncommon. This approach to dosing is commonly referred to as the “maximal dose” strategy.
- the compounds are administered to a subject at a dose of about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg.
- the effective amount may be less than when the agent is used alone. Dosing may be once per day or multiple times per day for one or more consecutive days.
- Compounds 1-3 and 5-8 are commercially available from Chembridge Corporation.
- Compound 9 is commercially available from Asinex.
- Compound 10 is commercially available from InterbioScreen Ltd.
- Compounds 11 and 32-41 are commercially available from Chemdiv Inc.
- Compounds 12-27 and 31 are commercially available from Enamine.
- Compound 4 is commercially available from Labotest (LT00160569).
- Compounds 28-30 are commercially available from Princeton Biomolecular Research. Remaining compounds were obtained from commercially available sources as indicated below, or were synthesized. The following compounds were used as HCl salts: Compounds 2, 4, 6-8, 26, 27, 64-72, and 75-76.
- the rotational correlation time of the fluorophore (peptide labeled with fluorescein at N-terminus) changes significantly, resulting in a substantial increase in the measured fluorescence polarization and fluorescence anisotropy (excitation at 500 nm, emission at 525 nm).
- the fluorescence polarization (FP) assay was utilized to determine the K d for the binding of menin and the MLL peptide using a serial dilution of menin and 50 nM fluorescein-labeled MLL peptide.
- IC 50 values The effectiveness of compounds (IC 50 values) in inhibiting the menin-MLL interaction was determined in the FP competition experiments. Compounds that inhibit the interaction decrease the fluorescence anisotropy which is being used as a read-out for compound screening and for IC 50 determination.
- the same competition FP assay is used for screening compounds targeting menin and inhibiting the menin-MLL interaction.
- a time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized as a secondary assay (e.g. for confirmation of results), commercialized by CIS-BIO as homogeneous time-resolve fluorescence (HTRF) assay.
- TR-FRET time-resolved fluorescence resonance energy transfer
- HTRF homogeneous time-resolve fluorescence
- the HTRF assay may be the primary assay and the FP assay is used as a secondary assay to confirm results.
- HTRF is based on the non-radiative energy transfer of the long-lived emission from the Europium cryptate (Eu 3+ -cryptate) donor to the allophycocyanin (XL665) acceptor, combined with time-resolved detection.
- Eu 3+ -cryptate Europium cryptate
- XL665 allophycocyanin
- Eu 3+ -cryptate-donor is conjugated with mouse anti-6His monoclonal antibody which binds His-tagged menin
- XL665-acceptor is conjugated to streptavidin (SA-XL665) which binds biotinylated MLL peptide.
- SA-XL665-acceptor is conjugated to streptavidin (SA-XL665) which binds biotinylated MLL peptide.
- SA-XL665-acceptor streptavidin
- NMR spectroscopy saturation transfer difference (STD), competition STD, and WaterLOGSY experiments to validate binding of compounds to menin.
- STD provides a reliable method, based on principles vastly different form fluorescence that is commonly used for drug screening (e.g. by pharmaceutical companies).
- the principle of the STD experiment is based on the transfer of magnetization from a protein to a small molecule. Such a transfer occurs only when the ligand-protein contact is direct, and can be detected when the ligand is in fast exchange between bound and unbound state (Mayer & Meyer. J Am Chem Soc., 2001. 123(25): p. 6108-17, herein incorporated by reference in its entirety).
- the difference spectrum of the ligand recorded with and without protein saturation is analyzed.
- the STD spectra of compounds in the presence of 2.5 ⁇ M of menin are measured.
- the sensitivity of the experiment is high due to the significant size of menin ( ⁇ 70 kDa).
- HTS high through-put screening
- the compounds were tested using FP with both fluorophores and HTRF, resulting in 5 compounds with IC 50 values below 100 ⁇ M.
- the most potent compound, Compound 1 had an IC 50 value of 1.9 uM.
- the most potent compounds can be clustered into two structural groups, indicating two classes (thienopyrimidine class and benzodiazepine class). Compounds from each cluster were tested by NMR, confirming they do bind to menin and compete with MLL for binding, which indicates their utility as anti-leukemia agents.
- Compound 1 was the most effecting inhibitory compound to arise out of screening performed during development of embodiments of the present invention.
- Compound 1 obtained from independent commercial suppliers, was re-tested by FP and HTRF for its inhibition of the menin-MLL interaction and obtained an identical IC 50 of 1.9 ⁇ M (Table 1).
- Two structurally related compounds were also identified in the same screening (Compound 2 and Compound 3, Table 1).
- 41 analogues of Compound 1 were purchased from commercial suppliers and 10 analogues were synthesized and tested for their inhibition of the menin-MLL interaction in FP assay resulting in a number of active compounds (Tables 1 and 2).
- Compound 4 demonstrates in vitro IC 50 comparable to the parent compound, but improved solubility, making it more suitable for cellular studies.
- Thienopyrimidine compounds active in inhibiting the MLL binding to menin in FP and HTRF assays were tested in NMR experiments to confirm their direct binding to menin and exclude any promiscuous inhibition (e.g. caused by aggregation, protein unfolding, precipitation, etc.).
- NMR ligand detecting methods e.g. STD, competition STD, WaterLOGSY, etc
- SEE FIG. 1A for representative spectra for Compound 1
- Compound 32 has demonstrated the most efficient inhibition from the benzodiazepine class of compounds identified by HTS.
- Two structurally related compounds identified in primary screening were also re-tested (Compound 33 and Compound 34, Table 3).
- compounds from the library with 85% similarity to Compound 32, which were not found as hits in primary screening were re-tested in dose response curves for their inhibition of the menin-MLL interaction, resulting in as number of active compounds (Table 3).
- Benzodiazepine compounds active in inhibiting the MLL binding to menin in FP and HTRF assays were tested in NMR experiments to confirm their direct binding to menin and exclude any promiscuous inhibition (e.g. caused by aggregation, protein unfolding, precipitation, other non-specific effects, etc.).
- the NMR ligand detecting methods e.g. STD, competition STD, WaterLOGSY, etc.
- STD competition STD
- WaterLOGSY WaterLOGSY
- Thienopyrimidine (Compound 64 labeled as MI-1, Compound 67 labeled as RJS-4-020, Compound 70 labeled as AS-1-19) and benzodiazepiene (Compound 32 labeled as MI-2 or CCG-21196) compounds were tested for their inhibition of the menin-MLL interaction in HEK293 cells transfected with Flag-MLL-AF9 by applying the co-Immunoprecipitation experiments (SEE FIGS. 2A-B ). Both classes of compounds can effectively inhibit this interaction in human cells at 50 ⁇ M and 25 ⁇ M compound concentration as compared to the DMSO control, demonstrating their potential as drug candidates for further development.
- Viability assay in human leukemia cell lines was performed with representative compounds from thienopyrimidine and benzodiazepine classes.
- Several cell lines, including the MV4;11, ML-2, KOPN-8, Karpas 45, MonoMac6 cell lines harboring different MLL translocation, were tested to evaluate compound effectiveness in inhibiting the growth of human leukemia cell lines.
- Very effective growth inhibition of human leukemia cell lines was observed for thienopyrimidine class of compounds:—Compound 64 (labeled as CCG — 21397 or MI-1), Compound 4 (labeled as CCG — 21397 — 25 or MI-1-25) (SEE FIG.
- Benzodiazepine compounds including Compound 32 (labeled as CCG — 21196 or MI-2), and Compound 86 (labeled as MI-2-12) also strongly inhibited growth of the MLL leukemia cells (SEE FIGS. 5A-B ).
- Compound 39 (labeled as MI-8), which was used as a negative control, showed no growth inhibition of the MLL leukemia cells, which correlates very well with the in vitro IC 50 value for this compound.
- Thienopyrimidine and benzodiazepiene compounds were tested in MTT viability assay to assess their effect on the growth of other leukemia cell lines without MLL translocations. Limited or no effect were observed for both classes of compounds (SEE FIGS. 6A-B ), demonstrating their selectivity for inhibiting the growth of MLL fusion cell lines.
- Thienopyrimidine compound (Compound 70 is AS-1-19) exhibits substantial inhibition of cell growth in mouse bone marrow transduced with MLL-AF9 and MLL-ENL fusion protein as measured by MTT cell viability assay (SEE FIG. 7 ). In contrast, no significant inhibition of cell growth was observed on mouse bone marrow transduced with E2A-HLF (pro-B-cell leukemia) was observed for this compound. This demonstrates again that thienopyrimidine compounds specifically inhibit growth of cells with MLL translocation.
- THP-1 MLL leukemia cells more pronounced effect was observed for benzodiazepine class of compounds: treatment with Compound 32 (labeled as MI-2) resulted in about 20% apoptotic cells and >40% of dead cells at 50 ⁇ M compound concentration.
- Thienopyrimidine Compound 64 (labeled as MI-1) resulted in a less pronounced effect, but apoptosis and cell death were induced as compared to DMSO control (SEE FIG. 8 ).
- THP-1 leukemia cells Treatment of THP-1 leukemia cells with thienopyrimidine (Compound 67 labeled as RJS-4-020 and Compound 70 labeled as AS-1-19) and benzodiazepine (Compound 32 labeled as MI-2) results in increased expression of CD11b on the cell surface (SEE FIG. 11 ), indicative of differentiation of these cells in response to compound treatment.
- thienopyrimidine Compound 67 labeled as RJS-4-020 and Compound 70 labeled as AS-1-19
- MI-2 benzodiazepine
- MFL Maybridge fragment library
- Compound 43 analogues have been evaluated to improve their potency in inhibiting the menin-MLL interaction. 15 compounds were tested, with the most active (6G10 — 3) being about 4 fold more potent than the original hit (Table 4).
Abstract
Description
- The present application is a continuation of U.S. patent application Ser. No. 12/875,968, filed Sep. 3, 2010, which claims priority to U.S. Provisional Patent Application Ser. No. 61/240,102, filed Sep. 4, 2009, each of which are herein incorporated by reference in their entireties.
- The invention relates generally to treatment of leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion oncoproteins, as well as systems and methods to screen for such compositions.
- Chromosomal translocations that affect the proto-oncogene Mixed Lineage Leukemia (MLL) occur in aggressive human acute leukemias, both in children and adults (Sorensen et al., J Clin Invest., 1994. 93(1): p. 429-37, Cox, et al., Am J Clin Pathol., 2004. 122(2): p. 298-306, herein incorporated by reference in their entireties). They are particularly common in infants with acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL) and constitute up to 80% of all infant acute leukemia cases. Fusion of MLL with one of 60 partner genes forms a chimeric oncogene which upregulates HOX genes resulting in a blockage of blood cell differentiation that ultimately leads to acute leukemia (Eguchi et al. Int J Hematol., 2003. 78(5): p. 390-401, herein incorporated by reference in its entirety). Patients with leukemias harboring MLL translocations have a very poor prognosis (35% five year survival) and it is clear that novel therapeutic strategies are urgently needed to treat these leukemias (Slang. Hematol Oncol., 2005. 23(1): p. 1-9, herein incorporated by reference in its entirety). Menin is a critical cofactor in MLL-associated leukemias. Menin is a tumor-suppressor protein encoded by the Multiple Endocrine Neoplasia (MEN) gene. Menin is a ubiquitously expressed nuclear protein that is engaged in interactions with a cohort of transcription factors, chromatin modifying proteins, and DNA processing and repair proteins (Agarwal et al. Horm Metab Res., 2005. 37(6): p. 369-74, herein incorporated by reference in its entirety). The biological function of menin remains unclear and is context dependent. It functions as a tumor suppressor in endocrine organs (Marx. Nat Rev Cancer., 2005. 5(5): p. 367-75, herein incorporated by reference in its entirety) but has an oncogenic role in myeloid cells (Yokoyama et al., Cell., 2005. 123(2): p. 207-18, herein incorporated by reference in its entirety). Association of menin with oncogenic MLL fusion proteins constitutively up-regulates expression of HOX genes and impairs proliferation and differentiation of hematopoietic cells leading to leukemia development. Myeloid cells transformed with oncogenic MLL-AF9 fusion protein require menin for efficient proliferation (Chen et al., Proc Natl Acad Sci USA., 2006. 103(4): p. 1018-23, herein incorporated by reference in its entirety). Menin is also required to maintain oncogenic transformation induced by other MLL translocations, including MLL-ENL, MLL-GAS7 and MLL-AF6 (Yokoyama et al., Cell., 2005. 123(2): p. 207-18, herein incorporated by reference in its entirety), demonstrating that menin functions as a general oncogenic cofactor in MLL-related leukemias and implies the interaction of menin with MLL fusions is a valuable target for molecular therapy. The leukemogenic activity of MLL fusion oncoproteins is dependent on association with menin. Therefore, selective targeting of this interaction could provide an attractive therapeutic approach to develop novel drugs for the MLL-related leukemias.
- In some embodiments, the present invention provides compositions for the treatment of leukemia which inhibit binding of one or more MLL fusion proteins to menin and/or MLL wild type to menin. In some embodiments, the composition comprises a thienopyrimidine class compound. In some embodiments, the thienopyrimidine class compound is of the general formula or pharmaceutically acceptable salts of thereof:
- wherein R1, R2, R3, R4, R5, R6, R7, and R8 independently comprise: H, alkyl (e.g., methyl, ethyl, etc.) which might be further substituted or non-substituted, alkoxy further substituted or non-substituted, a halogen (e.g. F, Cl, Br, I, and At), a ketone, a carbocyclic ring, an aromatic ring, a heterocyclic aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, a heterocyclic non-aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic aromatic or non-aromatic ring attached or fused to the thienopyrimidine ring system non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic or heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members fused to another aromatic ring, or a hydrogen bond donor or a hydrogen bond acceptor. Z is S or O or NH or CH—CH. W is present or absent and is NH or NH—(CH2)n (n=0-10), or (CH2)n (n=0-10) or O or O—(CH2)n (n=0-10); X and Y are each independently N or C; m is 0-3 (where m=0, R7 is absent). In some embodiments, the present invention comprises any substituent that results in compounds inhibiting the interaction of menin with MLL and/or MLL fusion proteins that can be used to treat or prevent leukemia.
- In some embodiments, the thienopyrimidine class compound is of the general formula or pharmaceutically acceptable salts of thereof:
- In some embodiments, the thienopyrimidine class compound has the structure:
- In some embodiments, the thienopyrimidine class compound is selected from Compounds 1-31 and 60-83.
- In some embodiments, the composition comprises any structural analogues of compositions 1-31 and 60-83.
- In some embodiments, the composition comprises a benzodiazepine class compound. In some embodiments, the benzodiazepine class compound is of the general formula or pharmaceutically acceptable salts of thereof:
- wherein R1, R2, R3, and R4 independently comprise: H, alkyl which might be substituted or non-substituted, acetyl, alkoxy, a halogen (e.g. F, Cl, Br, I, and At), a ketone, a carbocyclic ring, an aromatic ring, a heterocyclic aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, a heterocyclic non-aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic aromatic or non-aromatic ring fused or attached to the benzodiazepine ring system non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic or heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members fused to another aromatic ring, or a hydrogen bond donor or a hydrogen bond acceptor. In some embodiments, the present invention comprises any substituent which result in compounds inhibiting the interaction of menin with MLL and/or MLL fusion proteins that can be used to treat or prevent leukemia.
- In some embodiments, the benzodiazepine class compound has the structure:
- In some embodiments, the benzodiazepine class compound is selected from: Compounds 32-41 and 84-86.
- In some embodiments, the compositions comprise structures of Compounds 42-59 or derivatives there.
- In some embodiments, the compositions comprise any structural analogues of compositions 35-41 and 84-86.
- The compositions may comprise combinations of any of the above compounds with one another or with other compounds of interest. Stereoisomers, salts, and derivates of the compounds are further contemplated.
- In some embodiments, the present invention provides a method comprising: administering a composition for the treatment of leukemia (e.g., which inhibits binding of one or more MLL fusion proteins to menin or MLL wild type to menin) to a subject suffering from leukemia. In some embodiments, the leukemia comprises AML or ALL. In some embodiments, the composition comprises a thienopyrimidine class compound. In some embodiments, the composition comprises a benzodiazepine class compound. In some embodiments, the composition comprises compounds 42-59 and their analogues.
- In some embodiments, the present invention provides a method of screening compounds effective in treating leukemia comprising assaying one or more compounds for inhibition of the interaction between MLL and menin. In some embodiments, the screening is performed in vitro. In some embodiments, the screening is performed in vivo. In some embodiments, the assaying comprises a fluorescence polarization assay. In some embodiments, the assaying comprises a time-resolved fluorescence resonance energy transfer assay. In some embodiments, the assaying comprises a nuclear magnetic resonance assay. In some embodiments, the assaying comprises cellular assays and mice studies.
- In some embodiments, the present invention provides a method of inhibiting the interaction of MLL and menin comprising: (a) providing: (i) a sample comprising MLL and menin and (ii) a composition configured to inhibit the interaction of MLL and menin, (b) administering the composition to the sample, (c) contacting MLL and/or menin with the composition, and (d) inhibiting the interaction between MLL and menin, and between MLL fusion proteins and menin. In some embodiments, the sample comprises cells from a subject suffering from leukemia. In some embodiments, the subject is a human subject or a human patient. In some embodiments, the cells are within a subject suffering from leukemia. In some embodiments, the composition comprises a thienopyrimidine class compound. In some embodiments, the composition comprises a benzodiazepine class compound. In some embodiments, the composition comprises compounds 42-59 and their analogues.
- In some embodiments, the present invention comprises any structural analogues of Compounds 1-86.
- The description provided herein is better understood when read in conjunction with the accompanying drawings which are included by way of example and not by way of limitation.
-
FIGS. 1A-B . A. Binding of Compound 1 (labeled as CCG21397; thienopyrimidine class) to menin demonstrated in STD (saturation transfer difference) experiment measured for 80 μM ofCompound 1 and 2.5 μM menin:reference 1D spectrum (black) showing separately aromatic and aliphatic regions; STD spectrum (red) showing binding ofCompound 1 to menin; competition STD spectrum (blue) showing the decrease of STD effect in the presence of 25 μM MLL peptide, which confirms specific binding ofCompound 1 to menin. The H and CH3 signals from the ligand shown on the spectra are labeled on the structure. B. Binding of Compound 33 (labeled as CCG23668; benzodiazepine class) to menin demonstrated in STD experiment measured for 100 μM Compound 33 and 2.5 μM menin:reference 1D spectrum (black) for the aliphatic region of the compound; STD spectrum (red) confirming binding to menin; competition STD spectrum (blue) showing the decrease of STD effect in the presence of 25 μM MLL peptide, which confirms specific binding of Compound 33 to menin. Signals from the ligand's methyl groups are labeled M1, M2 and M1′, M2′ (two sets of peaks are from different stereoisomers). The intensity of peak corresponding to impurity (labeled with asterix) is not affected by addition of MLL. -
FIGS. 2A-B . A. Co-Immunoprecipitation experiments in HEK293 cells transfected with Flag-MLL-AF9 treated with thienopyrimidine compound (MI-1=Compound 64) and benzodiazepine compound (MI-2=Compound 33) after 24 h incubation with each compound. B. Co-Immunoprecipitation experiments in HEK293 cells transfected with Flag-MLL-AF9 and treated with the most potent thienopyrimidine compounds: RJS-4-020=Compound 67, and AS-1-19=Compound 70 after 6 h incubation with each compound. -
FIGS. 3A-C . MTT viability assay of benzodiazepine (CCG-21196=Compound 33) and thienopyrimidine (CCG-21397=Compound 1 and CCG-21397-25=Compound 4) compounds in human liver (HepG2) and kidney (HK-2) cell lines showing no substantial signs of toxicity for these compounds. -
FIGS. 4A-B . A. ATP-based luminescence cell viability assay in human leukemia cell lines with different MLL translocations (MV4;11—MLL-AF4; ML-2—MLL-AF6; KONP8—MLL-ENL; Karpas45—MLL-AFX) treated with thienopyrimidine compounds (MI-1=Compound 64 and MI-1-25=Compound 4) demonstrating substantial growth inhibition of MLL leukemia cells. B. MTT viability assay for the most potent thienopyrimidine compound (AS-1-19=Compound 70) in human leukemia cell lines with MLL translocations (MV4;11 harboring MLL-AF4 fusion and MonoMac6 harboring MLL-AF9 fusion protein). -
FIGS. 5A-B . A. MTT cell viability assay in human leukemia cell lines with different MLL translocations (MV4;11—MLL-AF4; KONP8—MLL-ENL; THP-1—MLL-AF9) treated with benzodiazepine compounds (MI-2=Compound 32 and MI-8=Compound 39) demonstrating substantial growth inhibition of MLL leukemia cells by Compound 32 and no effect for Compound 39. These results correlate very well with the in vitro IC50 values for these compounds. B. MTT viability assay for the most potent benzodiazepine compound (MI-2-12=Compound 86) in human leukemia cell lines with MLL translocations (MV4;11 harboring MLL-AF4 fusion and MonoMac6 harboring MLL-AF9 fusion protein). -
FIGS. 6A-C . A. MTT cell viability assay with thienopyrimidine compounds (Compound 64=MI-1,Compound 4=MI-1-25 and Compound 63=MI-1-72) in non-MLL leukemia cell lines (Kasumi-1 harboring AML1-ETO and ME-1 harboring CBFβ-SMMHC fusion proteins). No or very limited effect is observed, confirming selectivity of these compounds to MLL-leukemia cell lines. B. MTT cell viability assay with the most potent thienopyrimidine compound (Compound 70=AS-1-19) in non-MLL leukemia cell lines (Kasumi-1 harboring AML1-ETO and ME-1 harboring CBFβ-SMMHC fusion proteins) showing no effect on the cell growth, demonstrating selectivity of this compound to the MLL-leukemia cells. C. MTT cell viability assay with the most potent benzodiazepine compound (Compounds 86=MI-2-12) in non-MLL leukemia cell lines (Kasumi-1 and ME-1) showing no or very limited effect on cell growth. -
FIG. 7 . MTT viability assay with thienopyrimidine compound (Compound 70=AS-1-19) in mouse bone marrow transduced with MLL-AF9, MLL-ENL and E2A-HLF (pro-B cell leukemia used as a negative control), demonstrating selectivity in inhibiting the growth of MLL fusion transduced mouse bone marrow. -
FIG. 8 . Annexin V/PI flow cytometry experiments with thienopyrimidine compounds (Compound 64=MI-1,Compound 4=MI-1-25) and benzodiazepine compound (Compound 32=MI-2) in MLL fusion leukemia cell lines (MV4;11 with MLL-AF4 and THP-1 with MLL-AF9). All compounds induce substantial apoptosis and cell death at 25 μM and 50 μM concentrations. -
FIGS. 9A-B . Luciferase reporter assay performed in HEK293 cells transfected with MLL-AF9 showing the effect of compounds on transactivation of Hoxa9 promoter: A) Inhibition of transactivation of Hoxa9 promoter by thienopyrimidine compound (MI-1=Compound 64, RJS-3-080 was used as a negative control); B) Effect for benzodiazepine compounds (MI-2=Compound 32 showing dose dependent inhibition, MI-8=Compound 39 was used as a negative control). -
FIGS. 10A-B . Effect of compounds on expression level of MLL downstream targets: Hoxa9 and Meis1 in THP-1 leukemia cells as measured by qRT-PCR experiments: A) Downregulation of Hoxa9 expression by thienopyrimidine compounds (RJS-3-082=Compound 65, AS-1-19=Compound 70, MI-1-72=Compound 63); B) Downregulation of Hoxa9 and Meis1 expression by benzodiazepine compound (MI-2-12=Compound 86). -
FIGS. 11A-B . Differentiation of THP-1 leukemia cells measured by the expression level of CD11b using flow cytometry: A) Effect for thienopyrimidine compounds (RJS-4-020=Compound 67, AS-1-19=Compound 70); B) Benzodiazepine compound (MI-2=Compound 32). -
FIG. 12 . Determination of IC50 by NMR spectroscopy. - The term “system” refers a group of objects, compounds, methods, and/or devices that form a network for performing a desired objective.
- As used herein a “sample” refers to anything capable of being subjected to the compositions and methods provided herein. The sample may be in vitro or in vivo. In some embodiments, samples are “mixture” samples, which samples from more than one subject or individual. In some embodiments, the methods provided herein comprise purifying or isolating the sample. In some embodiments, the sample is purified or unpurified protein. In some embodiments, a sample may be from a clinical or research setting. In some embodiments, a sample may comprise cells, fluids (e.g. blood, urine, cytoplasm, etc.), tissues, organs, lysed cells, whole organisms, etc. In some embodiments, a sample may be derived from a subject. In some embodiments, a sample may comprise one or more partial or whole subjects.
- As used herein, the term “subject” refers to any animal including, but not limited to, insects, humans, non-human primates, vertebrates, bovines, equines, felines, canines, pigs, rodents (e.g., mice), and the like. The terms “subject” and “patient” may be used interchangeably, wherein the term “patient” generally refers to a subject seeking or receiving treatment or preventative measures from a clinician or health care provider. A subject may be of any stage of life (e.g. embryo, fetus, infant, neonatal, child, adult, live, dead, etc.).
- As used herein, the term “subject at risk for cancer” refers to a subject with one or more risk factors for developing a specific cancer. Risk factors include, but are not limited to, gender, age, genetic predisposition, environmental exposure, and previous incidents of cancer, preexisting non-cancer diseases, and lifestyle.
- As used herein, the term “characterizing cancer in subject” refers to the identification of one or more properties of a cancer sample in a subject, including but not limited to, the presence of benign, pre-cancerous or cancerous tissue or cells and the stage of the cancer. Cancers may be characterized by identifying cancer cells with the compositions and methods of the present invention.
- The terms “test compound” and “candidate compound” refer to any chemical entity, pharmaceutical, drug, and the like that is a candidate for use to treat or prevent a disease, illness, sickness, or disorder of bodily function (e.g., cancer). Test compounds comprise both known and potential therapeutic compounds. A test compound can be determined to be therapeutic by screening using the screening methods of the present invention.
- As used herein, the term “effective amount” refers to the amount of a compound (e.g., a compound having a structure presented above or elsewhere described herein) sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages and is not limited to or intended to be limited to a particular formulation or administration route.
- As used herein, the term “co-administration” refers to the administration of at least two agent(s) (e.g., a compound having a structure presented above or elsewhere described herein) or therapies to a subject. In some embodiments, the co-administration of two or more agents/therapies is concurrent. In other embodiments, a first agent/therapy is administered prior to a second agent/therapy. Those of skill in the art understand that the formulations and/or routes of administration of the various agents/therapies used may vary. The appropriate dosage for co-administration can be readily determined by one skilled in the art. In some embodiments, when agents/therapies are co-administered, the respective agents/therapies are administered at lower dosages than appropriate for their administration alone. Thus, co-administration is especially desirable in embodiments where the co-administration of the agents/therapies lowers the requisite dosage of a known potentially harmful (e.g., toxic) agent(s).
- As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo, in vivo or ex vivo.
- As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants. (See e.g., Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, Pa. [1975]).
- As used herein, the term “pharmaceutically acceptable salt” refers to any pharmaceutically acceptable salt (e.g., acid or base) of a compound of the present invention which, upon administration to a subject, is capable of providing a compound of this invention or an active metabolite or residue thereof. As is known to those of skill in the art, “salts” of the compounds of the present invention may be derived from inorganic or organic acids and bases. Examples of acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
- Examples of bases include, but are not limited to, alkali metals (e.g., sodium) hydroxides, alkaline earth metals (e.g., magnesium), hydroxides, ammonia, and compounds of formula NW4 +, wherein W is C1-4 alkyl, and the like.
- Examples of salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, undecanoate, and the like. Other examples of salts include anions of the compounds of the present invention compounded with a suitable cation such as Na+, NH4 +, and NW4 + (wherein W is a C1-4 alkyl group), and the like.
- For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
- As used herein, the term “instructions for administering said compound to a subject,” and grammatical equivalents thereof, includes instructions for using the compositions contained in a kit for the treatment of conditions characterized by viral infection (e.g., providing dosing, route of administration, decision trees for treating physicians for correlating patient-specific characteristics with therapeutic courses of action). The compounds of the present invention (e.g. as shown in structures above and elsewhere presented herein) can be packaged into a kit, which may include instructions for administering the compounds to a subject.
- In some embodiments, the present invention provides compositions and methods for prevention and/or treatment of leukemia (e.g. MLL-related leukemia and other acute leukemias). In some embodiments, the present invention provides compositions and method for the inhibition of the protein-protein interaction between menin and MLL fusion proteins and/or menin and MLL wild type protein. In some embodiments, compositions and methods inhibit the interaction that is important for the oncogenic (e.g. leukemogenic) potential of MLL fusions. In some embodiments, the present invention provides small molecule inhibitors of interactions between menin and MLL fusion proteins and/or menin and MLL wild type protein. In some embodiments, compositions and methods reverse (e.g. inhibit, decrease, abolish, etc.) the oncogenic (e.g. leukemogenic) potential of MLL fusions. In some embodiments, compositions find utility in targeted therapies (e.g. anti-leukemia agents). In some embodiments, compounds block menin-MLL interactions.
- In some embodiments, the present invention provides compositions which inhibit the interaction between MLL (e.g. MLL fusion proteins and MLL wild type) and menin. In some embodiments, any compounds, small molecules (e.g. pharmaceuticals, drugs, drug-like molecules, etc.), macromolecules (e.g. peptides, nucleic acids, etc.) and/or macromolecular complexes which inhibit the MLL-menin interaction find utility in the present invention. In some embodiments, the present invention provides small molecule compounds which inhibit MLL-menin interactions. In some embodiments, compositions of the present invention decrease the affinity of menin for MLL (e.g. MLL fusion proteins) and/or MLL (e.g. MLL wild type protein) for menin. In some embodiments, compositions of the present invention disrupt bonding (e.g. hydrogen bonding, ionic bonding, covalent bonding, etc.), molecular interactions (e.g. hydrophobic interactions, electrostatic interactions, van der Waals interactions, etc.), shape recognition, and/or molecular recognition between MLL (e.g. MLL fusion proteins or MLL wild type protein) and menin. However, an understanding of the mechanisms of action is not required to practice the invention and the invention is not limited to any particular mechanism of action.
- The present invention provides any small molecules or classes of small molecules which disrupt, target, or inhibit MLL/menin interactions; and/or treat/prevent leukemia. In some embodiments, small molecules are effective in inhibiting the interaction of MLL-fusion proteins with menin or MLL wild type protein with menin. In particular embodiments, the present invention provides thienopyrimidine and benzodiazepine classes of small molecules. In some embodiments, thienopyrimidine and benzodiazepine small molecules inhibit the interaction of MLL (e.g. MLL-fusion proteins or MLL wild type) with menin. In some embodiments, thienopyrimidine and benzodiazepine small molecules inhibit the oncogenic (e.g. leukemogenic) effects of MLL-fusion proteins, and/or MLL-menin and MLL fusion protein-menin interactions. In some embodiments, thienopyrimidine and benzodiazepine small molecules treat and/or prevent leukemia (e.g. MLL-dependant leukemias, MLL-related leukemias, or other leukemias with and without high level of Hox gene expression etc.).
- In some embodiments, thienopyrimidine class small molecules are of the general structures:
- or pharmaceutically acceptable salts or hydrates thereof, wherein: R1, R2=H, alkyl which might be substituted or non-substituted, alkoxy further substituted or non-substituted, a halogen (e.g. F, Cl, Br, I, and At), a carbocyclic aromatic ring, a carbocyclic aromatic ring comprising six carbons, a carbocyclic non-aromatic ring, a carbocyclic non-aromatic ring of three to six carbons, a heterocyclic aromatic ring, a five or six member heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members, any aromatic or non-aromatic ring non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, a five or six member heterocyclic non-aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members, a carbocyclic aromatic or non-aromatic ring fused to the thienopyrimidine ring system, a five or six member carbocyclic aromatic or non-aromatic ring fused to the thienopyrimidine ring system, any aromatic or non-aromatic ring system non-substituted or substituted with alkyl, halogen, hydrogen bond donor or acceptor fused to thienopyrimidine ring system, a five or six member carbocyclic or heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members fused to another aromatic ring substituted or non-substituted, or a hydrogen bond donor or a hydrogen bond acceptor; in some embodiments R1 and R2 are covalently bound to one another (e.g., exist within a ring); R3, R4, R5, R6, R7, and R8=H, alkyl substituted or non-substituted, alkoxy, a halogen (e.g. F, Cl, Br, I, and At), a carbocyclic aromatic ring comprising six carbons, a carbocyclic non-aromatic ring of three to six carbons, a five or six member heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members, a five or six member heterocyclic non-aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members, any aromatic or non-aromatic ring non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, a five or six member carbocyclic or heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members fused to another aromatic ring, a hydrogen bond donor or a hydrogen bond acceptor, etc. Z is S or O or NH or CH—CH. W is present or absent and is NH or NH—(CH2)n (n=0-10), or (CH2)n (n=0-10) or O or O—(CH2)n (n=0-10); X and Y are each independently N or C; m is 0-3 (where m=0, R7 is absent). In some embodiments, R1, R2, R3, and R4 comprise any substituents which result in compounds which inhibit the interaction of MLL-fusion proteins with menin and/or treat or prevent leukemia.
- In some embodiments, thienopyrimidine class small molecules comprise the compositions of Tables 1 and 2, derivatives, combinations, pharmaceutically acceptable salts, and/or hydrates thereof. In some embodiments, thienopyrimidine class small molecules inhibit the interaction of MLL (e.g. MLL fusion proteins) with menin. In some embodiments, thienopyrimidine class small molecules reverse and/or inhibit the oncogenic (e.g. leukemogenic) effects of MLL-fusion proteins, and/or MLL/menin and MLL fusion proteins/menin interactions. In some embodiments, thienopyrimidine class small molecules prevent or treat leukemia.
- In some embodiments, benzodiazepine class small molecules are of the general structure:
- or pharmaceutically acceptable salt or hydrate thereof, wherein: R1, R2, R3, R4=H, alkyl, acetyl, alkoxy, ketone, a halogen (e.g. F, Cl, Br, I, and At), a carbocyclic aromatic ring, a carbocyclic aromatic ring comprising six carbons, a carbocyclic non-aromatic ring, a carbocyclic non-aromatic ring of three to six carbons, a heterocyclic aromatic ring, a five or six member heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members, a heterocyclic non-aromatic ring, a five or six member heterocyclic non-aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members, a five or six member carbocyclic or heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members fused to alkyl, alkoxy, halogen (e.g. F, Cl, Br, I, and At), a hydrogen bond donor, a hydrogen bond acceptor or to another aromatic or non-aromatic ring, a five or six member heterocyclic non-aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members fused to another aromatic ring, a hydrogen bond donor or a hydrogen bond acceptor, etc. In some embodiments, R1, R2, R3, and R4 comprise any substituents which result in compounds which inhibit the interaction of MLL-fusion proteins with menin and/or treat or prevent leukemia.
- In some embodiments, benzodiazepine class small molecules comprise the compositions of Table 3, derivatives, combinations, pharmaceutically acceptable salts, and/or hydrates thereof. In some embodiments, benzodiazepine class small molecules inhibit the interaction of MLL (e.g. MLL fusion proteins or MLL wild type) with menin. In some embodiments, benzodiazepine class small molecules reverse and/or inhibit the oncogenic (e.g. leukemogenic) effects of MLL, MLL-fusion proteins, and/or MLL/menin interactions. In some embodiments, benzodiazepine class small molecules prevent or treat leukemia.
- In some embodiments, the compound has the structure of Compounds 42-59, or derivatives thereof.
- In some embodiments, the present invention provides administration of compositions of the present invention to subjects (e.g. leukemia patients) to treat or prevent disease (e.g. cancer, leukemia, MLL-related leukemia, etc.). In some embodiments, the present invention provides administration of compositions for the treatment or prevention of leukemia (e.g. acute leukemias, chronic leukemias, lymphoblastic leukemias, lymphocytic leukemias, myeloid leukemias, myelogenous leukemias, Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia (CLL), Acute myelogenous leukemia (AML), Chronic myelogenous leukemia (CML), Hairy cell leukemia (HCL), T-cell prolymphocytic leukemia (T-PLL), Large granular lymphocytic leukemia, MLL-positive leukemias, MLL-induced lukemias, etc.).
- In some embodiments, any of the above compounds is co-administered or used in combination with a known therapeutic agent (e.g., methotrexate, 6-mercaptopurine, antibody therapies, etc.).
- In some embodiments, the compositions of the present invention are provided as pharmaceutical and/or therapeutic compositions. The pharmaceutical and/or therapeutic compositions of the present invention can be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration can be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional carriers; aqueous, powder, or oily bases; thickeners; and the like can be necessary or desirable. Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders can be desirable. Compositions and formulations for parenteral, intrathecal or intraventricular administration can include sterile aqueous solutions that can also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients. Pharmaceutical and/or therapeutic compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome containing formulations. These compositions can be generated from a variety of components that include, but are not limited to, preformed liquids, self emulsifying solids and self emulsifying semisolids.
- The pharmaceutical and/or therapeutic formulations of the present invention, which can conveniently be presented in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical/nutriceutical industries. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product. The compositions of the present invention can be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention can also be formulated as suspensions in aqueous, non aqueous, oil-based, or mixed media. Suspensions can further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension can also contain stabilizers. In one embodiment of the present invention the pharmaceutical compositions can be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product.
- Dosing and administration regimes are tailored by the clinician, or others skilled in the pharmacological arts, based upon well known pharmacological and therapeutic considerations including, but not limited to, the desired level of therapeutic effect, and the practical level of therapeutic effect obtainable. Generally, it is advisable to follow well-known pharmacological principles for administrating chemotherapeutic agents (e.g., it is generally advisable to not change dosages by more than 50% at time and no more than every 3-4 agent half-lives). For compositions that have relatively little or no dose-related toxicity considerations, and where maximum efficacy is desired, doses in excess of the average required dose are not uncommon. This approach to dosing is commonly referred to as the “maximal dose” strategy. In certain embodiments, the compounds are administered to a subject at a dose of about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg. When the compounds described herein are co-administered with another agent (e.g., as sensitizing agents), the effective amount may be less than when the agent is used alone. Dosing may be once per day or multiple times per day for one or more consecutive days.
- Compounds 1-3 and 5-8 are commercially available from Chembridge Corporation. Compound 9 is commercially available from Asinex.
Compound 10 is commercially available from InterbioScreen Ltd., Compounds 11 and 32-41 are commercially available from Chemdiv Inc. Compounds 12-27 and 31 are commercially available from Enamine.Compound 4 is commercially available from Labotest (LT00160569). Compounds 28-30 are commercially available from Princeton Biomolecular Research. Remaining compounds were obtained from commercially available sources as indicated below, or were synthesized. The following compounds were used as HCl salts:Compounds - Fluorescence Polarization Assay.
- Assays effective in monitoring the inhibition of the MLL binding to menin were developed during experiments performed during the development of embodiments of the present invention. A fluorescein-labeled 12-amino acid peptide derived from MLL containing the high affinity menin binding motif was produced (Yokoyama et al., Cell., 2005. 123(2): p. 207-18, herein incorporated by reference in its entirety). Upon binding of the peptide (1.7 kDa) to the much larger menin (−67 kDa), the rotational correlation time of the fluorophore (peptide labeled with fluorescein at N-terminus) changes significantly, resulting in a substantial increase in the measured fluorescence polarization and fluorescence anisotropy (excitation at 500 nm, emission at 525 nm). The fluorescence polarization (FP) assay was utilized to determine the Kd for the binding of menin and the MLL peptide using a serial dilution of menin and 50 nM fluorescein-labeled MLL peptide. The titration curve demonstrates nanomolar affinity (Kd=56 nM) for the menin-MLL interaction.
- The effectiveness of compounds (IC50 values) in inhibiting the menin-MLL interaction was determined in the FP competition experiments. Compounds that inhibit the interaction decrease the fluorescence anisotropy which is being used as a read-out for compound screening and for IC50 determination. For validation of the FP assay, a control competition experiment with unlabeled MLL peptide (no fluorescein attached) was performed. The competitive displacement of the fluorescein-labeled MLL peptide from menin by unlabeled MLL peptide was monitored. Using this assay, the IC50 value for the MLL peptide with menin: IC50=0.23 μM. In some embodiments of the present invention, the same competition FP assay is used for screening compounds targeting menin and inhibiting the menin-MLL interaction.
- HTRF Assay.
- One potential limitation of the above FP assay is the risk of selection of compounds that may interfere with the FP assays and produce so called “false-positives”. Therefore, during development of embodiments of the present invention, a time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized as a secondary assay (e.g. for confirmation of results), commercialized by CIS-BIO as homogeneous time-resolve fluorescence (HTRF) assay. In some embodiments, the HTRF assay may be the primary assay and the FP assay is used as a secondary assay to confirm results. HTRF is based on the non-radiative energy transfer of the long-lived emission from the Europium cryptate (Eu3+-cryptate) donor to the allophycocyanin (XL665) acceptor, combined with time-resolved detection. When these two fluorophores are brought together by a biomolecular interaction, a portion of the energy captured by the Eu3+-cryptate during excitation at 337 nm is released through fluorescence emission of donor at 620 nm, while remaining energy is transferred to XL665 acceptor and released as specific fluorescence at 665 nm. In the HTRF used in the present invention, and development of embodiments thereof, Eu3+-cryptate-donor is conjugated with mouse anti-6His monoclonal antibody which binds His-tagged menin, and XL665-acceptor is conjugated to streptavidin (SA-XL665) which binds biotinylated MLL peptide. The interaction of menin with the MLL peptide brings together donor and acceptor resulting in energy transfer to acceptor reflected by the increased fluorescence emission at 665 nm and increased HTRF ratio (emission intensity at 665 nm/emission intensity at 620 nm). Inhibition of the menin-MLL interaction by a competitor separates donor from acceptor, resulting in decreased emission at 665 nm and decreased HTRF ratio. The assay was validated by running the titration experiment with unlabeled MLL peptide, which resulted in IC50=2.3 μM, remaining in a good agreement with the FP data.
- NMR Spectroscopy Validation of Lead Compounds.
- In embodiments of the present invention, and during development thereof, NMR spectroscopy: saturation transfer difference (STD), competition STD, and WaterLOGSY experiments to validate binding of compounds to menin. STD provides a reliable method, based on principles vastly different form fluorescence that is commonly used for drug screening (e.g. by pharmaceutical companies). The principle of the STD experiment is based on the transfer of magnetization from a protein to a small molecule. Such a transfer occurs only when the ligand-protein contact is direct, and can be detected when the ligand is in fast exchange between bound and unbound state (Mayer & Meyer. J Am Chem Soc., 2001. 123(25): p. 6108-17, herein incorporated by reference in its entirety). The difference spectrum of the ligand recorded with and without protein saturation is analyzed. To detect binding of compounds to menin the STD spectra of compounds in the presence of 2.5 μM of menin are measured. The sensitivity of the experiment is high due to the significant size of menin (−70 kDa).
- Library Screening.
- During development of embodiments of the present invention, high through-put screening (HTS) of 65,000 compounds tested at 20 μM has been carried out to identify compounds targeting the menin-MLL interaction. Primary screening was performed using FP. About 1400 compounds demonstrated inhibition in primary screening, out of which 240 re-confirmed. 180 compounds with no significant interference with FP (as confirmed in a non-FP assay) were selected for dose response curves (DRC), which was carried out by two independent FP assays: FLSN_MLL and Texas Red_MLL as fluorophores (TR_MLL was used to exclude “false positives” interfering with fluorescein). DRC demonstrated 40 compounds which were active in both FP assays. After detailed analysis, 16 compounds were selected for further analysis. The compounds were tested using FP with both fluorophores and HTRF, resulting in 5 compounds with IC50 values below 100 μM. The most potent compound,
Compound 1, had an IC50 value of 1.9 uM. The most potent compounds can be clustered into two structural groups, indicating two classes (thienopyrimidine class and benzodiazepine class). Compounds from each cluster were tested by NMR, confirming they do bind to menin and compete with MLL for binding, which indicates their utility as anti-leukemia agents. -
Compound 1 was the most effecting inhibitory compound to arise out of screening performed during development of embodiments of the present invention.Compound 1, obtained from independent commercial suppliers, was re-tested by FP and HTRF for its inhibition of the menin-MLL interaction and obtained an identical IC50 of 1.9 μM (Table 1). Two structurally related compounds were also identified in the same screening (Compound 2 andCompound 3, Table 1). In addition, 41 analogues ofCompound 1 were purchased from commercial suppliers and 10 analogues were synthesized and tested for their inhibition of the menin-MLL interaction in FP assay resulting in a number of active compounds (Tables 1 and 2).Compound 4 demonstrates in vitro IC50 comparable to the parent compound, but improved solubility, making it more suitable for cellular studies.Compound 1 was converted to HCl salt resulting in Compound 64 which improved its solubility. Synthesized compounds: 65, 66, 67, 70 showed more potent activity in in vitro FP assay (Table 2), with the most potent Compound 70 (IC50=0.43 μM). Tables land 2 list IC50 data for a number of active compounds from the thienopyrimidine class. -
TABLE 1 Structures and activities for thienopyrimidine class of compounds measured by FP and HTRF. NA-no activity, NS-no saturation on titration curve. IC50 values <100 μM are in bold. IC50 in HTRF IC50 in FP assay with assay Compound Structure FLSN-MLL (μM) (μM) Compound 11.9 1.2 Compound 242 85 Compound 383 35 Compound 5 NS, delta at 150 μM = 12 % Compound 6 NA Compound 7 170 Compound 860 Compound 9 540 Compound 10250 Compound 11500 Compound 12NA up to 100 uM Compound 13 NS, delta at 1 mM = 20% Compound 14 250 Compound 15 49 Compound 1671 Compound 17 NA up to 250 uM Compound 18 NS, delta at 500 uM = 35% Compound 19 NS, delta at 1 mM = 40 % Compound 20 125 Compound 21 50 Compound 22 NS, delta at 500 μM = 20% Compound 23 NS, delta at 250 μM = 20% Compound 24 NA up to 1 mM Compound 25 NS, delta at 1 mM = 40% Compound 26 NS, delta at 1 mM = 15% Compound 27 350 Compound 43.8 Compound 28 NS, delta at 0.5 mM = 30% Compound 29 NA up to 250 μM Compound 30 NS, delta at 0.5 mM = 17% Compound 31 29.5 -
TABLE 2 Structures and activities for thienopyrimidine class of compounds. NA-no activity, NS-no saturation on titration curve. IC50 values <100 μM are in bold. ID Structure IC50 (μM) Vendor cat # Compound 60 30 PrincetonBio OSSK_851527 Compound 61 20 Enamine T6333361 Compound 62 10 ChemBridge 5728395 Compound 63 12 Asinex BAS 00933720 Compound 64 Compound 1 converted to HCl salt1.9 Labotest LT01870086 Compound 65 1.2 synthesized Compound 66 1.1 synthesized Compound 67 0.65 synthesized Compound 68 2.4 synthesized Compound 69 16 synthesized Compound 70 0.43 synthesized Compound 71 4.6 synthesized Compound 724.8 synthesized Compound 73 20 Enamine T5902760 Compound 74 7 Enamine T6210441 Compound 75 32 synthesized Compound 76 6.3 synthesized Compound 77 8.7 ChemDiv G786-0963 Compound 78 12 Enamine T0518-1385 Compound 79 20 Enamine T5225244 Compound 80 1.3 ChemDiv G887-0164 Compound 81 40 ChemDiv G887-0168 Compound 82 4.4 ChemDiv G887-0335 Compound 83 27 ChemDiv G887-0354 - Binding of Thienopyrimidine Compounds to Menin Measured by NMR.
- Thienopyrimidine compounds active in inhibiting the MLL binding to menin in FP and HTRF assays were tested in NMR experiments to confirm their direct binding to menin and exclude any promiscuous inhibition (e.g. caused by aggregation, protein unfolding, precipitation, etc.). NMR ligand detecting methods (e.g. STD, competition STD, WaterLOGSY, etc) were used to confirm their binding to menin (SEE
FIG. 1A for representative spectra for Compound 1). - Synthesis of Thienopyrimidine Compounds.
- Compounds 65-72 were synthesized according to the the
synthetic Scheme 1. The condensation ofaldehyde 1 withethyl cyanoacetate 2 and elemental sulfur using triethyl amine as a base (Gewald reaction) affordedthiophene 3. Treatments ofcompound 3 withformamide 4 under heating conditions (120° C.) lead to the formation of thienopyrimidine 5. Chlorination was achieved by refluxing compound 5 in oxalyl chloride to yieldcompound 6. Nucleophilic substitution of 6 withpiperazine 7 providedcompound 8, which was then converted to the HCl salt 9. - Compound 32 has demonstrated the most efficient inhibition from the benzodiazepine class of compounds identified by HTS. Compound 32 was re-tested by FP and HTRF for its inhibition of the menin-MLL interaction, resulting in IC50=13 μM (Table 3). Two structurally related compounds identified in primary screening were also re-tested (Compound 33 and Compound 34, Table 3). In addition, compounds from the library with 85% similarity to Compound 32, which were not found as hits in primary screening, were re-tested in dose response curves for their inhibition of the menin-MLL interaction, resulting in as number of active compounds (Table 3). Table 3 lists IC50 data for a number of active compounds from the benzodiazepine class. 12 commercially available analogues of Compound 32 were ordered and tested, resulting in one compound with a better IC50 (Compound 86, IC50=7.4 μM) than the original compound. Active compounds are shown in Table 3.
-
TABLE 3 Structures and activities for benzodiazepine class of compounds measured by FP and HTRF. NA-no activity, ND-not determined, IC50 values <100 μM are in bold. IC50 in FP assay with IC50 in FLSN- HTRF MLL Vendor/Cat assay Compound Structure (μM) # (μM) Compound 32 13 ChemDiv Inc. Cat # 4780- 0051 7 Compound 33 29 ChemDiv Inc. Cat # 5742- 0717 28 Compound 34 12 ChemDiv Inc. Cat # 3393- 0109 ND Compound 35 35 ChemDiv Inc. Cat # 3393- 0126 ND Compound 36 63 ChemDiv Inc. Cat # 3170- 5216 ND Compound 37 100 ChemDiv Inc. Cat # 3404- 5359 ND Compound 38 115 ChemBridge Cat # 6369841 ND Compound 39 230 ChemDiv Inc. Cat # 3170- 5232 ND Compound 40 NA ChemDiv Inc. Cat # 5531- 8211 ND Compound 41 NA ChemDiv Inc. Cat # 3770- 0060 ND Compound 84 100 Interbioscreen STOCK2S- 89112 ND Compound 85 72 ChemBridge 8879201 ND Compound 86 7.4 ChemBridge 8879215 ND - Binding of Benzodiazepine Compounds to Menin Measured by NMR.
- Benzodiazepine compounds active in inhibiting the MLL binding to menin in FP and HTRF assays were tested in NMR experiments to confirm their direct binding to menin and exclude any promiscuous inhibition (e.g. caused by aggregation, protein unfolding, precipitation, other non-specific effects, etc.). The NMR ligand detecting methods (e.g. STD, competition STD, WaterLOGSY, etc.) were used to confirm their binding to menin (SEE
FIG. 1B for representative spectra for Compound 33). - Inhibition of the Menin-MLL Interaction in Human Cells.
- Thienopyrimidine (Compound 64 labeled as MI-1, Compound 67 labeled as RJS-4-020, Compound 70 labeled as AS-1-19) and benzodiazepiene (Compound 32 labeled as MI-2 or CCG-21196) compounds were tested for their inhibition of the menin-MLL interaction in HEK293 cells transfected with Flag-MLL-AF9 by applying the co-Immunoprecipitation experiments (SEE
FIGS. 2A-B ). Both classes of compounds can effectively inhibit this interaction in human cells at 50 μM and 25 μM compound concentration as compared to the DMSO control, demonstrating their potential as drug candidates for further development. - Effects of Thienopyrimidine and Benzodiazepine Compounds in Kidney and Liver Cell Lines.
- The effectiveness of compounds from thienopyrimidine and benzodiazepine classes were tested in human cell lines. Effects on cell growth were assayed using the MTT viability assay (Mosmann. Immunol Methods., 1983; 65(1-2):55-63, herein incorporated by reference in its entirety). The viability assay (MIT) with Hep-G2 (liver) and HK-2 (kidney) cell lines resulted in no signs of substantial toxicity for both classes of compounds (SEE
FIGS. 3A-C .Compound 1 labeled asCCG 21397,Compounds 4 labeled asCCG —21397—25, Compound 32 labeled as CCG—21196). - Effects of Thienopyrimidine and Benzodiazepine Compounds on Growth Inhibition of Human Leukemia Cell Lines with MLL Translocations.
- Viability assay in human leukemia cell lines was performed with representative compounds from thienopyrimidine and benzodiazepine classes. Several cell lines, including the MV4;11, ML-2, KOPN-8, Karpas 45, MonoMac6 cell lines harboring different MLL translocation, were tested to evaluate compound effectiveness in inhibiting the growth of human leukemia cell lines. Very effective growth inhibition of human leukemia cell lines was observed for thienopyrimidine class of compounds:—Compound 64 (labeled as
CCG —21397 or MI-1), Compound 4 (labeled asCCG —21397—25 or MI-1-25) (SEEFIG. 4A ), with the GI50 values at low micromolar range: 7-25 μM, and for Compound 70 (labeled as AS-1-19) (SEEFIG. 4B ), which is the most potent compound out of thienopyrimidine class in in vitro FP experiment (Tables 1 and 2). - Benzodiazepine compounds, including Compound 32 (labeled as
CCG —21196 or MI-2), and Compound 86 (labeled as MI-2-12) also strongly inhibited growth of the MLL leukemia cells (SEEFIGS. 5A-B ). In contrast, Compound 39 (labeled as MI-8), which was used as a negative control, showed no growth inhibition of the MLL leukemia cells, which correlates very well with the in vitro IC50 value for this compound. - Specificity of Thienopyrimidine and Benzodiazepine Compounds to MLL Leukemia Cells.
- Thienopyrimidine and benzodiazepiene compounds were tested in MTT viability assay to assess their effect on the growth of other leukemia cell lines without MLL translocations. Limited or no effect were observed for both classes of compounds (SEE
FIGS. 6A-B ), demonstrating their selectivity for inhibiting the growth of MLL fusion cell lines. - Effects of Thienopyrimidine Compounds on Mouse Bone Marrow Transduced with MLL-AF9 and MLL-ENL.
- Thienopyrimidine compound (Compound 70 is AS-1-19) exhibits substantial inhibition of cell growth in mouse bone marrow transduced with MLL-AF9 and MLL-ENL fusion protein as measured by MTT cell viability assay (SEE
FIG. 7 ). In contrast, no significant inhibition of cell growth was observed on mouse bone marrow transduced with E2A-HLF (pro-B-cell leukemia) was observed for this compound. This demonstrates again that thienopyrimidine compounds specifically inhibit growth of cells with MLL translocation. - Thienopyrimidine and Benzodiazepine Compounds Induce Apoptosis in MLL Leukemia Cells.
- Compounds from both classes were assessed for their ability to induce apoptosis in MLL leukemia cell lines (MV4;11 and THP-1) using the Annexin V/PI staining flow cytometry experiments (SEE
FIG. 8 ). Both classes of compounds can effectively induce apoptosis and cell death in MLL fusion cells lines at low micromolar concentration (25-50 μM). This effect is more pronounced in MLL-AF4 cells (>20% of apoptotic cells at 25 μM of Compound 64 labeled as MI-1 and Compound 32 labeled as MI-2 and more than 20% of dead cells in the same experimental conditions). In THP-1 MLL leukemia cells, more pronounced effect was observed for benzodiazepine class of compounds: treatment with Compound 32 (labeled as MI-2) resulted in about 20% apoptotic cells and >40% of dead cells at 50 μM compound concentration. Thienopyrimidine Compound 64 (labeled as MI-1) resulted in a less pronounced effect, but apoptosis and cell death were induced as compared to DMSO control (SEEFIG. 8 ). - Effect of Thienopyrimidine and Benzodiazepine Compounds on MLL Fusion Downstream Targets Hoxa9 and Meis1.
- The effect of both classes of compounds on expression of MLL fusion downstream targets was assessed in the luciferase reporter assay (SEE
FIG. 9 ) and by RT-PCR (SEEFIG. 10 ). Both classes of compounds (Compound 64 labeled as MI-1 and Compound 32 labeled as MI-2) can effectively inhibit the transactivation of the Hoxa9 promoter in the luciferase reporter assay in HEK293 cell transfected with MLL-AF9. No effect was observed for the negative control compounds: (RJS-3-080 and Compound 39 labeled as MI-8), which correlates well with the in vitro IC50 values. Furthermore, the downregulation of Hoxa9 expression was also observed in the RT-PCR experiments performed in THP-1 cells for both classes of compounds (SEEFIG. 10 ), with a more pronounced effect after 7 days of incubation time with compounds. These compounds also decreased the expression level of Meis1, which is another downstream target of MLL (SEEFIG. 10 b). - Thienopyrimidine and Benzodiazepine Compounds Induce Differentiation of the MLL Leukemia Cells.
- Treatment of THP-1 leukemia cells with thienopyrimidine (Compound 67 labeled as RJS-4-020 and Compound 70 labeled as AS-1-19) and benzodiazepine (Compound 32 labeled as MI-2) results in increased expression of CD11b on the cell surface (SEE
FIG. 11 ), indicative of differentiation of these cells in response to compound treatment. - Experiments were conducted to screen a subset of the Maybridge fragment library (MFL) (500 compounds with diverse molecular scaffolds, drug-like properties and molecular weight below 300 Da) using the FP assay. The MFL was screened for the competitive displacement of the fluorescein-labeled MLL peptide from menin using FP.
- The screening of the MFL resulted in 20 compounds showing >25% inhibition of the MLL peptide binding to menin at 500 μM concentration, which were subsequently tested in a dose dependent manner to determine the IC50 values. Compounds which interfered with the assay (precipitation, intrinsic fluorescence) were considered as false positives and excluded from further analysis. Finally, 11 compounds were obtained with diverse molecular scaffolds which inhibited the menin-MLL interaction with the IC50 values below 2 mM. Binding to menin was confirmed for 4 compounds (Compounds 42 (4H8), 43 (6G10), 44 (1F4), and 45 (4A6) by applying NMR spectroscopy with the most potent compound, Compound 42 (IC50=50 μM) (
FIG. 12 ). - Compound 43 analogues have been evaluated to improve their potency in inhibiting the menin-MLL interaction. 15 compounds were tested, with the most active (6G10—3) being about 4 fold more potent than the original hit (Table 4).
-
TABLE 4 Structures and activities of hits from MFL and 6G10 analogues measured by FP and HTRF. NA- no activity, ND-not determined IC50 in FP assay with IC50 in FLSN-MLL Vendor/ HTRF assay Compound Structure (μM) Cat # (μM) 1F4 Compound 44 380 Maybridge BTB 03582 4H8 Compound 42 50 Maybridge CC39814 4A6 Compound 45 510 Maybridge CC35409 6G10 Compound 43 230 ChemBridge Corporation 6956708 200 6G10_1 Compound 46 2000 Maybridge SB02074 ND 6G10_3 Compound 47 67 Enamine T5648583 33 6G10_4 Compound 48 NS, D 0.5 mM = 30% Life Chemicals F1643-0298 ND 6G10_5 Compound 49 NS, D 1.0 mM = 10% Sigma L119199 ND 6G10_6 Compound 50 122 Enamine T5972333 ND 6G10_7 Compound 51 1900 Enamine T5428144 ND 6G10_8 Compound 52 107 Enamine T5709338 ND 6G10_9 Compound 53 1060 Enamine T5882535 ND 6G10_10 Compound 54 137 Enamine T5668711 ND 6G10_11 Compound 55 NA Enamine T5670346 ND 6G10_12 Compound 56 NS, D 0.5 mM = 30% Enamine T5657444 ND 6G10_13 Compound 57 1200 Enamine T5665037 ND 6G10_14 Compound 58 80 Enamine T5647112 ND 6G10_85 Compound 59 830 Enamine T5665035 ND
Claims (25)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/665,600 US20160045504A1 (en) | 2009-09-04 | 2015-03-23 | Compositions and methods for treatment of leukemia |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24010209P | 2009-09-04 | 2009-09-04 | |
US12/875,968 US8993552B2 (en) | 2009-09-04 | 2010-09-03 | Compositions and methods for treatment of leukemia |
US14/665,600 US20160045504A1 (en) | 2009-09-04 | 2015-03-23 | Compositions and methods for treatment of leukemia |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/875,968 Continuation US8993552B2 (en) | 2009-09-04 | 2010-09-03 | Compositions and methods for treatment of leukemia |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160045504A1 true US20160045504A1 (en) | 2016-02-18 |
Family
ID=43649670
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/875,968 Active US8993552B2 (en) | 2009-09-04 | 2010-09-03 | Compositions and methods for treatment of leukemia |
US14/665,600 Abandoned US20160045504A1 (en) | 2009-09-04 | 2015-03-23 | Compositions and methods for treatment of leukemia |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/875,968 Active US8993552B2 (en) | 2009-09-04 | 2010-09-03 | Compositions and methods for treatment of leukemia |
Country Status (7)
Country | Link |
---|---|
US (2) | US8993552B2 (en) |
EP (1) | EP2473054B1 (en) |
JP (2) | JP5792171B2 (en) |
CN (1) | CN102984941B (en) |
AU (2) | AU2010289321A1 (en) |
CA (1) | CA2773131C (en) |
WO (1) | WO2011029054A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017192543A1 (en) | 2016-05-02 | 2017-11-09 | Regents Of The University Of Michigan | Piperidines as menin inhibitors |
US10077271B2 (en) | 2015-06-04 | 2018-09-18 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
WO2018183857A1 (en) | 2017-03-31 | 2018-10-04 | The Regents Of The University Of Michigan | Piperidines as covalent menin inhibitors |
US10246464B2 (en) | 2014-09-09 | 2019-04-02 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
WO2020072391A1 (en) | 2018-10-03 | 2020-04-09 | The Regents Of The University Of Michigan | Small molecule menin inhibitors |
US10752639B2 (en) | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
US10781218B2 (en) | 2016-03-16 | 2020-09-22 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
WO2021067215A1 (en) | 2019-09-30 | 2021-04-08 | Agios Pharmaceuticals, Inc. | Piperidine compounds as menin inhibitors |
WO2021204159A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
WO2021207310A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
WO2022086937A1 (en) * | 2020-10-21 | 2022-04-28 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as degraders of enl |
US11472799B2 (en) | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
US11510920B2 (en) | 2016-10-28 | 2022-11-29 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating EZH2-mediated cancer |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
US11541051B2 (en) | 2016-12-08 | 2023-01-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
US11649251B2 (en) | 2017-09-20 | 2023-05-16 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI1007379B8 (en) | 2009-01-06 | 2022-07-19 | Curemark Llc | pharmaceutical compositions for the treatment or prevention of oral infections by e. coli |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
SG178592A1 (en) | 2009-09-03 | 2012-04-27 | Bristol Myers Squibb Co | Quinazolines as potassium ion channel inhibitors |
WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
EP3239154A1 (en) | 2011-01-10 | 2017-11-01 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
GB201114212D0 (en) * | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
WO2013068592A1 (en) * | 2011-11-10 | 2013-05-16 | Fondation Jerome Lejeune | Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide |
AR090037A1 (en) | 2011-11-15 | 2014-10-15 | Xention Ltd | DERIVATIVES OF TIENO AND / OR FURO-PYRIMIDINES AND PYRIDINES INHIBITORS OF THE POTASSIUM CHANNELS |
WO2013106535A1 (en) | 2012-01-10 | 2013-07-18 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
CA2861464C (en) | 2012-01-25 | 2018-03-06 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating tricyclic compounds |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
EP2671575A1 (en) * | 2012-06-04 | 2013-12-11 | Universität Regensburg | Ras inhibitors |
PE20150228A1 (en) | 2012-06-11 | 2015-02-19 | Bristol Myers Squibb Co | 5- [5-PHENYL-4- (PYRIDIN-2-ILMETHYLAMINE) QUINAZOLIN-2-IL] PYRIDIN-3-SULFONAMIDE PHOSPHORAMID ACID PROPHARM |
US9085586B2 (en) | 2012-07-11 | 2015-07-21 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
CA2878040A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
CA2883894C (en) | 2012-09-06 | 2020-08-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
NZ706857A (en) * | 2012-09-28 | 2018-05-25 | Ignyta Inc | Azaquinazoline inhibitors of atypical protein kinase c |
GB201217704D0 (en) * | 2012-10-03 | 2012-11-14 | Ucb Pharma Sa | Therapeutic agents |
US20140136295A1 (en) | 2012-11-13 | 2014-05-15 | Apptio, Inc. | Dynamic recommendations taken over time for reservations of information technology resources |
US9175007B2 (en) | 2013-01-10 | 2015-11-03 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
WO2014127191A1 (en) | 2013-02-15 | 2014-08-21 | The Regents Of The University Of Michigan | Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins |
JP2016512514A (en) | 2013-03-13 | 2016-04-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Compositions containing thienopyrimidine and thienopyridine compounds and methods for their use |
CN104119343A (en) * | 2013-04-25 | 2014-10-29 | 苏州科捷生物医药有限公司 | 2-trifluoromethyl thiadiazole compound and application thereof |
MX2016003843A (en) | 2013-09-27 | 2017-02-15 | Nimbus Iris Inc | Irak inhibitors and uses thereof. |
TWI648281B (en) * | 2013-10-17 | 2019-01-21 | 日商安斯泰來製藥股份有限公司 | Sulfur-containing bicyclic compound |
JP2017001954A (en) * | 2013-11-08 | 2017-01-05 | 石原産業株式会社 | Nitrogen-containing saturated heterocyclic compound |
CN104892589A (en) | 2014-03-07 | 2015-09-09 | 中国科学院上海药物研究所 | Heterocyclic compound, preparation method therefor and use thereof |
AU2015228386A1 (en) * | 2014-03-11 | 2016-09-22 | Godavari Biorefineries Limited | Cancer stem cell targeting compounds |
US10526341B2 (en) * | 2014-11-19 | 2020-01-07 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
CN104592248A (en) * | 2014-12-31 | 2015-05-06 | 芜湖杨燕制药有限公司 | Preparation method of 4-chlorine-6-substituted thieno [2,3-d] pyrimidine compound |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
EP3407884A4 (en) | 2016-01-26 | 2019-09-11 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression innpm1 |
WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
TWI753016B (en) | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Fused bicyclic inhibitors of menin-mll interaction |
TWI738864B (en) | 2016-09-14 | 2021-09-11 | 比利時商健生藥品公司 | Spiro bicyclic inhibitors of menin-mll interaction |
US11220517B2 (en) * | 2016-09-14 | 2022-01-11 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
ES2901227T3 (en) * | 2016-12-15 | 2022-03-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-MLL interaction |
EA201991448A1 (en) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | AZEPAN INTERACTION INHIBITORS MENIN-MLL |
EA038388B1 (en) * | 2017-01-16 | 2021-08-19 | Кура Онколоджи, Инк. | Substituted inhibitors of menin-mll and methods of use |
US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
CN112105621B (en) | 2018-03-30 | 2024-02-20 | 住友制药株式会社 | Optically active bridged cyclic secondary amine derivatives |
WO2021063346A1 (en) * | 2019-09-30 | 2021-04-08 | 上海迪诺医药科技有限公司 | Kras g12c inhibitor and application thereof |
CN111297863B (en) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | Application of menin-MLL inhibitor in preparation of medicine for treating endometrial cancer |
CN117321049A (en) | 2021-05-08 | 2023-12-29 | 詹森药业有限公司 | Substituted spirocyclic derivatives |
WO2022237627A1 (en) | 2021-05-08 | 2022-11-17 | Janssen Pharmaceutica Nv | Substituted spiro derivatives |
US20230250096A1 (en) | 2021-06-01 | 2023-08-10 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES |
BR112023025436A2 (en) | 2021-06-03 | 2024-02-27 | Janssen Pharmaceutica Nv | PYIDAZINES OR 1,2,4-TRIAZINES REPLACED BY SPIROCYCLIC AMINES |
IL309359A (en) | 2021-06-17 | 2024-02-01 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008099019A1 (en) * | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10330377A (en) * | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | Piperidine derivative |
PA8474101A1 (en) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS |
EP1382603B1 (en) | 2001-04-26 | 2008-07-23 | Eisai R&D Management Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
CN100343258C (en) * | 2001-04-30 | 2007-10-17 | 美国拜尔公司 | Novel 4-amino-5,6-substituted thiopheno 2,3-d]pyrimidines |
US7115741B2 (en) * | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
AU2003258662A1 (en) * | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
JP5335191B2 (en) | 2003-08-22 | 2013-11-06 | デンドレオン コーポレイション | Compositions and methods for treating diseases associated with Trp-p8 expression |
US20050123906A1 (en) | 2003-11-06 | 2005-06-09 | Rana Tariq M. | Protein modulation |
CA2573103A1 (en) | 2004-07-06 | 2006-02-09 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
US20060281771A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
MX2008003032A (en) * | 2005-09-02 | 2008-03-24 | Tibotec Pharm Ltd | Benzodiazepines as hcv inhibitors. |
CA2651898A1 (en) * | 2006-04-07 | 2007-10-18 | Develogen Aktiengesellschaft | Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
FR2913017A1 (en) | 2007-02-23 | 2008-08-29 | Cerep Sa | New N-(substituted alkyl)-piperidine or piperazine derivatives, are cellular proliferation inhibitors useful e.g. for treating cancer or inflammatory or autoimmune diseases |
EP2150527B1 (en) | 2007-03-19 | 2011-01-19 | Council of Scientific & Industrial Research | Anthranilic acid derivative as anticancer agent and a process for the preparation thereof |
US20080293699A1 (en) | 2007-05-25 | 2008-11-27 | Burnham Institute For Medical Research | Inhibitors of thapsigargin-induced cell death |
WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
US20110124649A1 (en) * | 2007-11-09 | 2011-05-26 | The Johns Hopkins University | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
WO2010030757A2 (en) * | 2008-09-10 | 2010-03-18 | Kalypsys Inc. | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
TW201105674A (en) * | 2009-07-08 | 2011-02-16 | Leo Pharma As | Novel JAK receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof |
-
2010
- 2010-09-03 JP JP2012528106A patent/JP5792171B2/en active Active
- 2010-09-03 CN CN201080050708.8A patent/CN102984941B/en active Active
- 2010-09-03 WO PCT/US2010/047894 patent/WO2011029054A1/en active Application Filing
- 2010-09-03 EP EP10814591.3A patent/EP2473054B1/en active Active
- 2010-09-03 CA CA2773131A patent/CA2773131C/en active Active
- 2010-09-03 US US12/875,968 patent/US8993552B2/en active Active
- 2010-09-03 AU AU2010289321A patent/AU2010289321A1/en not_active Abandoned
-
2014
- 2014-06-27 AU AU2014203516A patent/AU2014203516B2/en active Active
-
2015
- 2015-03-23 US US14/665,600 patent/US20160045504A1/en not_active Abandoned
- 2015-05-13 JP JP2015098562A patent/JP2015143283A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008099019A1 (en) * | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
US10246464B2 (en) | 2014-09-09 | 2019-04-02 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
US10077271B2 (en) | 2015-06-04 | 2018-09-18 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
US10174041B2 (en) | 2015-06-04 | 2019-01-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
US11673898B2 (en) | 2016-03-16 | 2023-06-13 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
US11555041B2 (en) | 2016-03-16 | 2023-01-17 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
US10752639B2 (en) | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
US10781218B2 (en) | 2016-03-16 | 2020-09-22 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
US10899738B2 (en) | 2016-05-02 | 2021-01-26 | The Regents Of The University Of Michigan | Piperidines as menin inhibitors |
WO2017192543A1 (en) | 2016-05-02 | 2017-11-09 | Regents Of The University Of Michigan | Piperidines as menin inhibitors |
US11510920B2 (en) | 2016-10-28 | 2022-11-29 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating EZH2-mediated cancer |
US11541051B2 (en) | 2016-12-08 | 2023-01-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
US11045448B2 (en) | 2017-03-31 | 2021-06-29 | The Regents Of The University Of Michigan | Piperidines as covalent menin inhibitors |
WO2018183857A1 (en) | 2017-03-31 | 2018-10-04 | The Regents Of The University Of Michigan | Piperidines as covalent menin inhibitors |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
US11649251B2 (en) | 2017-09-20 | 2023-05-16 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
US11472799B2 (en) | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
WO2020072391A1 (en) | 2018-10-03 | 2020-04-09 | The Regents Of The University Of Michigan | Small molecule menin inhibitors |
WO2021067215A1 (en) | 2019-09-30 | 2021-04-08 | Agios Pharmaceuticals, Inc. | Piperidine compounds as menin inhibitors |
WO2021207310A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
WO2021204159A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
WO2022086937A1 (en) * | 2020-10-21 | 2022-04-28 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as degraders of enl |
WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
Also Published As
Publication number | Publication date |
---|---|
JP2013503906A (en) | 2013-02-04 |
WO2011029054A1 (en) | 2011-03-10 |
CN102984941B (en) | 2016-08-17 |
AU2010289321A1 (en) | 2012-04-05 |
CN102984941A (en) | 2013-03-20 |
EP2473054A1 (en) | 2012-07-11 |
JP2015143283A (en) | 2015-08-06 |
CA2773131A1 (en) | 2011-03-10 |
EP2473054A4 (en) | 2013-05-01 |
AU2014203516B2 (en) | 2016-06-09 |
CA2773131C (en) | 2015-07-14 |
EP2473054B1 (en) | 2017-06-14 |
JP5792171B2 (en) | 2015-10-07 |
US8993552B2 (en) | 2015-03-31 |
AU2014203516A1 (en) | 2014-07-17 |
US20110065690A1 (en) | 2011-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8993552B2 (en) | Compositions and methods for treatment of leukemia | |
US20190269801A1 (en) | Simvastatin and chemotherapeutic conjugates with a heptamethine carbocyanine dye resensitize human tumors to hormonal antagonists and chemotherapy | |
KR102511024B1 (en) | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | |
JP2022009090A (en) | Dosing of kras inhibitor for treatment of cancers | |
Yan et al. | Discovery of a PROTAC targeting ALK with in vivo activity | |
WO2011085039A2 (en) | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies | |
US11851445B2 (en) | Compounds and uses thereof | |
JP2009521484A (en) | 3-Aryl substituted quinazolones and uses thereof | |
US20220062291A1 (en) | Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a) with reduced inhibitory activity targeted to the dopamine d2 receptor and accompanying toxicity | |
BR112019017851A2 (en) | method for treating cancer in an individual who needs it, method for identifying an individual who has cancer as a candidate for treatment with a smarca2 antagonist, method for identifying a cancer cell as sensitive to treatment with a smarca2 antagonist, antagonist of smarca2 for use in the treatment of cancer in an individual who needs it, antagonist of smarca2 for use as a medicine in the treatment of cancer in an individual who needs it and use of the antagonist of smarca2 in the manufacture of a medicine in the treatment of cancer in an individual who needs the same | |
US20100316655A1 (en) | Compounds with mdr1-inverse activity | |
US20230072053A1 (en) | Compounds and uses thereof | |
WO2008157407A2 (en) | Thiadiazole, oxadiazole and triazole derivatives for treating leukemia | |
US8569360B2 (en) | Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling | |
US20230212126A1 (en) | Small-molecule inhibitors of the frs2-fgfr interaction and their use in medicine, in the prevention and treatment of cancer | |
US20150265608A1 (en) | Compounds for Treating Rac-GTPase Mediated Disorder | |
AU2016252029B2 (en) | Compounds for treating Rac-GTPase mediated disorder | |
Su et al. | Repurposing fluphenazine as an autophagy modulator for treating liver cancer | |
Zhang et al. | Anlotinib exerts an anti-T-cell acute lymphoblastic leukemia effect in vitro and in vivo | |
WO2023105008A1 (en) | Small-molecule inhibitors of the frs2-fgfr interaction | |
Fox | FROST450, a Novel Microtubule Targeting Agent: Resistance and Cross-Resistance in an Ovarian Cancer Cell Line | |
WO2019143833A1 (en) | Compounds for treating rac-gtpase mediated disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF VIRGINIA, VIRGINIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GREMBECKA, JOLANTA;CIERPICKI, TOMASZ;REEL/FRAME:035365/0592 Effective date: 20091119 Owner name: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, VIRGINIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITY OF VIRGINIA;REEL/FRAME:035365/0971 Effective date: 20091124 |
|
AS | Assignment |
Owner name: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, MICHIGA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HESS, JAY;REEL/FRAME:043259/0490 Effective date: 20090918 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |